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ABSTRACT 
Asthma-COPD Overlap: Economic Burden and Medication Adherence 
Mona Nili 
In many older adults, asthma and chronic obstructive pulmonary disease (COPD) coexist as 
“Asthma-COPD overlap” (ACO). This dissertation pursued three Aims: 1) estimate the 
economic burden of ACO and its contributory factors; 2) evaluate the association of ACO to 
“cost-related medication nonadherence” (CRN); and 3) identify adherence trajectory patterns and 
examine the impact of initial maintenance therapies (IMT) type (inhaled corticosteroids 
monotherapy (ICS) vs. fixed-dose combination of ICS and long-acting beta agonist 
(ICS/LABA)) on adherence trajectory patterns among older adults Medicare Beneficiaries. The 
first and second Aims were cross-sectional studies by using Medicare Current Beneficiary 
Survey data. For the third Aim, we used a longitudinal retrospective cohort design, using 10% 
sample of Optum’s Deidentified Clinformatics®. In this study, older adults with ACO had nearly 
four times higher average total healthcare expenditures compared to those no-asthma no-COPD 
(NANC). The higher number of medications and fragmented care were the leading contributors 
of the economic burden. Moreover, compared to older adults with NANC, those with ACO were 
more likely to report any CRN. This association was highly dependent on number of 
medications. In addition, we identified four medication adherence trajectories to IMT among 
older adults with ACO. Those who using ICS/LABA were less likely to have “persistent low 
adherence” (Adjusted Odds Ratio= 0.38). In summary, these findings highlight the need to 
reduce the economic burden and improve medication adherence among older adults with ACO. 




I dedicate this dissertation to my husband, M. Ray Arvand, Esq., and my mentor, Dr. Usha 
Sambamoorthi, who has always been extremely supportive and has set the cornerstone of my 
continued success in my career. 
iv 
ACKNOWLEDGEMENT 
First and foremost, I would like to express the deepest appreciation to my mentor Dr. 
Usha Sambamoorthi for her relentless guidance, support, and encouragement to pursue my 
dissertation idea. I am truly blessed to have a mentor like you. You are one of the most 
intelligent and humble people that I know. You believed in me those moments when I did not 
believe in myself. Without your constant oversight, feedback, and guidance, I would not have 
been able to complete this dissertation.  
I would also like to thank my committee members, Dr. Nilanjana Dwibedi, Dr. Traci 
LeMasters, Dr. Megan Adelman, and Dr. Suresh Madhavan, for serving as my committee 
members. I would like to thank Dr. Dwibedi for accepting all my last-minute requests and 
providing valuable feedbacks. I am grateful to Dr. LeMasters for providing timely feedback and 
for helping me improve my writing skills. Dr. Adleman: thank you for your prompt feedback, 
motivational emails and suggestions on clinical aspects of my dissertation. Dean Madhavan: I 
cannot thank you enough for all the numerous opportunities that you have provided to me over 
the years; you have truly played a critical role in grooming me as a researcher and a critical 
thinker.  
I am extremely thankful to West Virginia University, and all the faculty (Dr. Scott, Dr. 
Kelly, Dr. Kamal (the new Chair of the Department) and staff (Sherri, Deborah, Angie) and 
students of the PSP department for providing me the necessary support to succeed. I also want to 
acknowledge my wonderful cohort friends (Nazneen, Rudi, and Ikram) for being my biggest 
cheerleaders, for working through days and nights on projects with me before deadlines, and for 
giving me wonderful memories that I will always cherish. 
 v 
 Last but not the least, I would also like to thank my husband. I cannot thank you enough 
for your patience, 16 hours driving every two weeks from NYC to Morgantown, and all the 
wonderful BBQs to uplift my mood during stressful times. You always made me believe that I 
can do this. Thank you so much. I would like to acknowledge my family for their unconditional 
love and support which helped me throughout my life. I am extremely thankful to my mom for 
all the sacrifices she made for me to make me what I am today.  
  
 vi 
Table of Contents 
List of Tables ............................................................................................................................... viii 
List of Figures ................................................................................................................................ ix 
List of Appendices .......................................................................................................................... x 
List of Abbreviations ..................................................................................................................... xi 
1 Introduction .................................................................................................................................. 1 
1.1 Background and Significance ......................................................................................... 1 
1.2 Innovation ....................................................................................................................... 9 
1.3 Specific Aims ................................................................................................................ 10 
1.4 Approach ....................................................................................................................... 10 
2 Economic Burden of Asthma- Chronic Obstructive Pulmonary Disease Overlap (ACO) among 
Older Adults in the United States ................................................................................................. 14 
2.1 Abstract ............................................................................................................................... 14 
2.2 Introduction ......................................................................................................................... 15 
2.3 Methods............................................................................................................................... 17 
2.4 Results ................................................................................................................................. 22 
2.5 Discussion ........................................................................................................................... 25 
2.6 Limitation ............................................................................................................................ 28 
2.7 Conclusion .......................................................................................................................... 29 
3 Asthma-Chronic Obstructive Pulmonary Disease Overlap and Cost-Related Medication 
Nonadherence among Older Adults in the United States ............................................................. 34 
3.1 Abstract ............................................................................................................................... 34 
3.2 Introduction ......................................................................................................................... 35 
3.3 Methods............................................................................................................................... 36 
 vii 
3.4 Results ................................................................................................................................. 39 
3.5 Discussion ........................................................................................................................... 41 
3.6 Conclusion .......................................................................................................................... 44 
4 Impact of Initial Maintenance Therapy Type on Medication Adherence Trajectories among 
Older Adults with Asthma and COPD Overlap ............................................................................ 50 
4.1 Abstract ............................................................................................................................... 50 
4.2 Introduction ......................................................................................................................... 51 
4.3 Methods............................................................................................................................... 53 
4.4 Results ................................................................................................................................. 57 
4.5 Discussion ........................................................................................................................... 58 
4.6 Limitations .......................................................................................................................... 61 
4.7 Conclusion .......................................................................................................................... 61 
5 Summary and Conclusion .......................................................................................................... 67 
5.1 Summary of Findings and Discussion ................................................................................ 67 
5.2 Implications and Suggestions for Future Research ............................................................. 72 
5.3 Strengths and Limitations ................................................................................................... 75 
5.5 Conclusion .......................................................................................................................... 76 
6 References .................................................................................................................................. 77 




List of Tables  
Table 2.1 Unweighted N and Weighted Percentages of Characteristics by Asthma /COPD 
Categories (Column %) among Older (age > 65 years), Medicare Beneficiaries Medicare Current 
Beneficiary Survey, 2006-2013………………………………………………………..………...23 
Table 2.2 Post-Regression Decomposition Analyses among Older (age > 65 years) Medicare 
Beneficiaries, Medicare Current Beneficiary Survey, 2006-2013………………..……………...24  
Table 3.1 Unweighted N and Weighted Percentages of Characteristics by Asthma and Chronic 
Obstructive Pulmonary Disease (COPD) Status (Column %) among Older (age > 65 years) 
Medicare Beneficiaries, Medicare Current Beneficiary Survey, 2006-2013……………..……...46 
Table 3.2 Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence 
Intervals from Separate Logistic Regressions on Any Cost-related Medication Nonadherence 
among Older (age > 65 years) Medicare Beneficiaries, Medicare Current Beneficiary Survey, 
2006-2013…………………………………….………………………………………………….47 
Table 3.3 Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence 
Intervals from Separate Logistic Regressions on Specific Forms of CRN Older (age > 65 years) 
Medicare Beneficiaries, Medicare Current Beneficiary Survey, 2006-2013……………………48 
Table 4.1 Characteristics of Older Adults with Asthma-COPD Overlap by Initial Maintenance 
Therapy Options Inverse Probability Treatment Weighting, Optum Clinformatics 10% Sample, 
2007-2017………………………………………………………………………………………. 62 
Table 4.2 Characteristics of Older Adults with Asthma-COPD Overlap by Medication 
Adherence Trajectories Initiated on Maintenance Therapy Optum Clinformatics 10% Sample, 
2007-2017…………………………...…………………………………………………..……….63 
Table 4.3 Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence 
Intervals from Multinomial Logistic Regressions on Medication Adherence Trajectory Groups 
with Persistent High Adherence as Reference Group, Inverse Probability Treatment Weighting 
among Older Medicare Beneficiaries with ACO and Initiated on Maintenance Therapy, Optum 




List of Figures 
Figure 1.1 Conceptual Framework for Factors Associated with Healthcare Expenditures, 
Adapted from Anderson’s Model)………………………………………………………….…....11  
 
Figure 2.1 Total Healthcare Expenditures and High Out-of-Pocket Burden by Asthma/ COPD 
Categories among Older (age > 65 years) Medicare Beneficiaries, Medicare Current Beneficiary 
Survey, 2006-2013……………………………………….……………………………………....32  
 
Figure 3.1 Prevalence of any CRN and Specific Types of CRN by Asthma-COPD Status (i.e., 
Asthma-COPD Overlap, Asthma-Only, COPD-Only, Neither Asthma nor COPD) among Older 
(age > 65 years) Medicare Beneficiaries Medicare Current Beneficiary Survey, 2006-2013…...49 
 
Figure 4.1 Trajectories of Adherence to Initial Maintenance Therapy among Older (> 65 years 
old) Adults with Asthma-COPD Overlap, Optum Clinformatics 10% Sample, 2007-2017...…..66 
 
 x 
List of Appendices 
Appendix 7.1 Attrition Table of Individuals Included in the Analysis Based on Inclusion and 
Exclusion Criteria……………………...………………………………………...……..………90 
 
Appendix 7.2 Diagnosis Codes for Asthma and COPD……………………………………….91 
 
Appendix 7.3 Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare 
Beneficiaries................................................................................................................................92 
 
Appendix 7.4 Mean Annual Adjusted and Unadjusted Expenditure among Older (age > 65 
years) Medicare Beneficiaries Medicare Current Beneficiary Survey, 2006-2013………...…..93 
 
Appendix 7.5 Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% 
Confidence Intervals from Separate Logistic Regressions on High Out-of-Pocket Burden among 
Older (age > 65 years) Medicare Beneficiaries  Medicare Current Beneficiary Survey, 2006-
2013………………..……..………………..………………..………………..………………...94 
 
Appendix 7.6 Post-Regression Decomposition Analyses among Older (age > 65 years) Medicare 
Beneficiaries Medicare Current Beneficiary Survey, 2006-2013………………………………95 
 
Appendix 7.7 Attrition Table of Individuals Included in the Analysis Based on Inclusion and 
Exclusion Criteria……………………………………………………………………………....96 
 
Appendix 7.8 Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare 
Beneficiaries ………………………………………...…………………………………………97 
 
Appendix 7.9 Attrition Table of Individuals Included in the Analysis Based on Inclusion and 
Exclusion Criteria……………………………………........………………...………………….98 
 
Appendix 7.10 Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from Generalized 
Estimating Equation (GEE) on Adherence among older adults with ACO Who Newly Initiated 
Maintenance Therapy, Optum Clinformatics 10% Sample, 2008-2016.....................................99 
 
Appendix 7.11 Characteristics of Older Adults with Asthma-COPD Overlap by Initial 
Maintenance Therapy Options before Using Inverse Probability Treatment Weighting, Optum 
Clinformatics 10% Sample, 2007-2017……………………………………………………...100 
 xi 
List of Abbreviations 
ACO Asthma COPD Overlap 
AOR Adjusted odds ratio 
CI Confidence interval 
COPD Chronic Obstructive Pulmonary Disease 
CRN Cost-Related Medication Non-Adherence 
FFS Fee-for-service 
GBTM Group-Based Trajectory Modeling 
GEE Generalized Estimating Equations 
GLM  Generalized Linear Model 
HMO Health Maintenance Organization 
ICD-9 International Classification of Diseases, Ninth Revision, Clinical 
Modification 
ICD-10 International Classification of Diseases, Tenth Revision, Clinical 
Modification 
IPTW Inverse Probability of Treatment Weighting 
OOB Out of Bag  
OOP Out-of-pocket 
OR Odds Ratio 
SD Standard deviation 
SE Standard error 
SIG Significance 
UOR Unadjusted Odds Ratio 
US United States 
 1 
 
CHAPTER 1  
1 Introduction 
1.1 Background and Significance 
Epidemiology of Major Depressive Disorder 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are the two most common 
respiratory diseases in the world. Combined, more than 435 million adults suffer from asthma or 
COPD. 1,2. The economic burden of asthma ($82 billion in 20153) and COPD ($49 billion 
projected in 20204) in the United States are very high. Clinicians can easily make these 
distinctions. Asthma usually develops in childhood, has classic symptoms of chest tightness, 
wheezing, coughing, and dyspnea, and is more likely to be associated with atopic disorders. 
COPD usually manifests later in life with dyspnea and productive cough and more likely be 
associated with environmental factors such as tobacco smoking. 
Definition of Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)  
 In 2009, Gibson and Simpson reported that about half of the older patients with obstructive 
airway disease have overlapping symptoms of both asthma and COPD. They called this the 
asthma-COPD “overlap syndrome”5. In 2013,  “asthma-COPD overlap syndrome” (AOCS) was 
used to describe this condition which is still used in many studies6. However, recent studies have 
suggested that it is better to describe this condition as “asthma COPD overlap” (ACO) without 
using “syndrome” since there is no specific definition of syndrome for this condition7. Thus, in 
our study, we use the term ACO when asthma and COPD co-exist in the same individual.  
Prevalence of ACO 
 In the general population, the estimated prevalence of ACO varies widely across studies 
based on the definitional criteria of ACO and time period. Using the National Health and 
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Nutrition Examination Survey (NHANES)-III (1988–1994) data, Diaz-Guzman et al. estimated 
that the prevalence of ACO was 2.7%8. However, and estimated the prevalence of ACO was 
estimated at 0.96% in the period spanning 2007–2012.  Prevalence of ACO among individuals 
with COPD or Asthma.  
The prevalence of ACO among patients with either asthma or COPD is higher than the 
general population. According to the findings of a meta-analysis,  the global prevalence of ACO 
among patients with asthma is 26.5% and among patients with COPD is 29.6%9  However, the 
prevalence of ACO can be as high as An estimated 50% patients with asthma or COPD9. Among 
patients with obstructive lung diseases, the prevalence of ACO is less than 10% among younger 
patients (< 50 years) and more than 50 % among older patients (>80 years or older)10. Similar 
results on age distribution were found in the Italian population6. 
Disease Burden of ACO 
  Disease burden of a condition is often measured with morbidity, health-related quality of 
life, mortality, healthcare utilization and costs. ACO patients experience substantial disease 
burden. In terms of mortality, ACO may be associated with a higher mortality compared with 
either asthma or COPD. In the NHANES-III cohort, Diaz-Guzman et al found that the hazard 
ratio (HR) for mortality in ACO is the highest (1.8), compared with COPD (1.4) and asthma 
(1.2)8. These findings contrast with few other studies where ACO have not increased risk of 
negative consequences. For example, a study of older adults (>55 years old) with progressive 
obstructive airway disease found that COPD patients had a worse prognosis compared to patients 
with ACO11. Bai et al also found that patients with ACO had higher likelihood of better 
prognoses and lower mortality compared to patients with COPD alone, though with a heightened 
exacerbation frequency. 
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In a cohort of 17,088 COPD patients in Taiwan, ACO patients experienced almost twice 
as many acute respiratory events (i.e. acute respiratory failure, pneumonia, acute exacerbation, 
and cardiopulmonary arrest) than did the rest of the COPD cohort12. In the Latin American 
Project for the Investigation of Obstructive Lung Disease (PLATINO), patients with ACO had 
worse lung function, had more respiratory medications, experienced more exacerbations and 
hospitalizations and reported a worse perception of general health status than patients with only 
either asthma or COPD13.  
The prevalence of co-existing health conditions is also higher in ACO compared to either 
asthma or COPD. A population survey in the US found that patients with ACO found that 90% 
of respondents had at least one other co-existing condition (compared with 71% in asthma and 
84% in COPD)14. When analyzed by type of eight chronic comorbid conditions (e.g. 
cardiovascular diseases, diabetes, and depression), the prevalence of all eight conditions were 
higher in ACO compared to asthma, and six out of eight conditions were more prevalent in ACO 
compared to COPD. 
Economic burden of ACO 
The high morbidity burden experienced by patients with ACO may also translate into high 
healthcare utilization and high healthcare costs. Using the  2009 Korean National Health 
Insurance database on 185,147 COPD patients, Rhee et al found that those with ACO had a 
higher frequency of emergency department visits, hospitalization and intensive care unit visits 
than patients with only COPD15. In this study, healthcare utilization and costs were significantly 
higher for both outpatient and inpatient care for ACO patients compared to those with only 
COPD or only asthma15. In a retrospective cohort study in Taiwan, patients with ACO had the 
higher medication costs, and experienced more respiratory-related hospital visits compared to 
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patients with asthma or COPD16. In Canada, a retrospective cohort study reported that costs of 
medications and outpatient services were higher in ACO patients, but costs of hospitalizations 
were lower compared to patients with COPD. In this study, costs of non-respiratory conditions 
were lower in ACO, mainly due to lower costs of cardiovascular diseases. 
Most of the studies on economic burden of ACO has been conducted mainly outside the 
United States (US). There have been only two studies in the US on the economic burden of 
ACO.  A retrospective cohort analysis of commercial claims in the US, both asthma-related and 
all-cause health care expenditures were twice as high for patients with ACO compared to those 
with only asthma17. Among enrollees of Medicare Advantage Plan in 2004, Blanchett et al found 
that mean unadjusted respiratory-related health care expenditures were $7,240 for the patients 
with ACO and $5,158 for patients with COPD18. However, these studies were conducted a 
decade ago and the estimates are dated.  Furthermore, the contributing factors to the excess cost 
of ACO remains unknown. The presence of comorbidities, more frequent exacerbations, and 
higher healthcare and medication utilization may be the major drivers of this excess cost.  
The Importance of Medication Use in ACO 
 An important goal of ACO management is slowing the progression of the disease as there 
is no cure for ACO. Inhaler medications play an important role slowing the progression of the 
disease. For example, medication fluticasone furoate/vilanterole, as an ICS/LABA, has been 
shown to substantial improvement in lung functions19. Therefore, adherence to medication is 
expected to be important among individuals with ACO. Although very limited evidence support 
the effect of adherence to inhaler medication and clinical outcomes, previous studies among 
patients with COPD and asthma support this20,21. 
Link between Medication Nonadherencee and Economic Burden 
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 Medication non-adherence is generally a source of considerable cost to the U.S. health 
care system22. Because medication adherence can accelerate the progression of the disease 
leading to hospitalizations, emergency room visits and other healthcare services.  Osterberg and 
Blaschke estimated that medication non-adherence contributes to approximately $100 billion in 
hospitalizations and $2,000 per patient annually in excess physician visits.23 Among Medicare 
beneficiaries with COPD, Simoni-Wastila et al estimated that patients who were not adherent to 
their medications had $2,185 higher costs compared with patients who adhered to their 
medication24. Specific to asthma and COPD, medication adherence to maintenance therapy is 
critical to slow the progression of disease. For example, a retrospective cohort study reported that 
poor adherence to initial maintenance therapy  was associated with progression of disease among 
patients with moderate to severe asthma25. 
Medication Nonadherencee among Adults with ACO 
  As there are no published studies on medication adherence among ACO patients, we 
speculate that ACO patients may be particularly vulnerable to medication non-adherence based 
on published literature focusing on either asthma or COPD or chronic respiratory conditions. As 
asthma and COPD are chronic conditions, patients with ACO are expected to use medications for 
asthma as well as COPD for the remainder of their lives. In general, medication adherence 
among patients with chronic pulmonary disease is lower compared to other chronic conditions, 
including rheumatologic conditions, HIV, cancer, and gastrointestinal disorders26 In a systematic 
review with more than 2,000 subjects with asthma using ICS, medication adherence ranged from 
47% to 57%27. Similarly, a study of 244 patients with COPD reported that adherence to 
ICS/LABA was less than 23%28. Non-adherence with long-acting bronchodilators was found 
among 65% of 45,000 patients with COPD in Germany29.  This number was 70% among 11,000 
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COPD patients in the US Veterans Affairs database30. Poor adherence to maintenance therapy is 
particularly higher among the elderly population. In a retrospective cohort study on Medicare 
beneficiaries with COPD, the average monthly adherence to IMT was very low31. In this study, 
the highest medication adherence was in the second month (0.57) and decreased rapidly before 
plateauing at 0.35 by the seventh month31.  
Higher Vulnerability of Older Adults with ACO to Medication Non-Adherence 
 Older adults with ACO may be at higher risk for medication non-adherence due to high 
medications costs32. Specifically, adherence to maintenance therapy may also be lower due to 
therapy-related factors such as medication type, ease of administration, ease of dosing33. While 
high cost of medications and medication-related factors can affect adherence among all patients 
with ACO, the older patients may be at a higher risk due to a unique set of circumstance (such as 
the high prevalence of comorbid conditions, low socio-economic status, and high rates of 
polypharmacy). 
Cost Related Medication Non-Adherence (CRN) among Older Adults with ACO 
 The primary socioeconomic factors influencing medication non-adherence are access to 
prescription benefits and out-of-pocket  expenses34. Without appropriate drug coverage, 
maintenance medications are cost prohibitive as generic maintenance medications have not been 
available in the United States35. In the US, most older patients are covered by Medicare 
insurance36. Although since 2006 Medicare Part D provided prescription drug coverage to 
increase access to prescription medications for the elderly population, most Medicare plans have 
drug coverage gaps (e.g. donut hole) that can create financial distress for the elderly patients37. 
High out-of-pocket contributions can increase CRN among elderly Medicare beneficiaries38. 
Moreover, formulary tiers make some of the most effective maintenance medications 
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inaccessible35. Affected older patients often respond to the drug coverage gap by using cost-
coping behaviors (e.g. forgoing mortgage payments) and CRN behaviors (e.g. skipping some 
doses of medication for stretching medication possession time)39. Medicare beneficiaries with 
chronic health conditions have a higher risk of CRN behaviors.40–42 In 2006 Castaldi et al 
estimated that the prevalence of CRN is 31% among Medicare beneficiaries with chronic 
pulmonary diseases (e.g. asthma or COPD).32 They did not specify which chronic pulmonary 
diseases increases the risk of CRN. By considering the negative health outcomes of ACO, we 
patients with ACO may be at high risk of CRN. 
Treatment-Related Factors and Medication Non-Adherence 
 Type and complexity of treatment are some of the many medication-related factors that 
may affect adherence to maintenance therapy among patients with asthma and COPD 
medications35. Most of the elderly patients are required to take multiple medications each day; 
many of these medications need more than one daily dose. ACO patients, who are already on 
complex regimens, adhering to complex regimen maintenance medications is challenging43 and 
consequently may lead to medication non-adherence. Furthermore, maintenance medications use 
inhalers and older patients may face challenges in self-administering inhaler medications. 
Misperceptions about maintenance medications may also lead to medication nonadherence older 
patients44. For instance, fast relief by using short-acting bronchodilator can be perceived as a 
measure of potency. This can result in mistakenly prioritized short acting bronchodilators over 
maintenance medicines (e.g. ICS). Fears of addiction to ICS or developing a tolerance is also 
very common which can lead to poor adherence to maintenance medications45.  
  
 8 
Possible Impact of Medication Type on Medication Non-Adherence  
 The joint guidelines of GINA and GOLD for treating ACO recommend ICS for IMT. The 
other IMT option for patients with ACO is ICS/LABA. The earliest use of ICS/LABA for IMT 
in treatment for ACO patients is supported by a study conducted by Gershon and colleagues46. In 
a case-control study, they demonstrated that newly prescribed ICS/LABA therapy, compared 
with LABA alone, was associated with a significantly lower risk of COPD hospitalization or 
death among ACO patients. Moreover, in a 12-week randomized open-label cross-over study, 
ACO patients experienced significant improvement in vital capacity after eight weeks ICS-
LABA treatment19. Prescribing ICS/LABA as IMT for ACO has two main advantages. First, 
ACO has both inflammatory and obstructive nature. Therefore, adding LABA to ICS can reduce 
obstruction. Second, using LABA is associated with a decreased risk of myocardial infarction, 
hospitalization, and death among patients with ACO47.  
Although both ICS and ICS/LABA are possible options for IMT of ACO, their impact on 
adherence is unknown. A study of asthma patients reported poor medication adherence to IMT 
when ICS is in fixed-dose combination with LABA (ICS/LABA) compared to ICS 
monotherapy48. As medication adherence in general declines over time for respiratory and other 
conditions, there is a need to examine trajectories of medication adherence among ACO patients 
by types of IMT. 
In summary, scientific studies of contributory factors to economic burden, cost-related 
mediation non-adherence and the impact of the type of maintenance therapy on adherence over 
time among ACO patients is non-existent. A deeper understanding of these issues is critical to 
providers as well as policy makers including CMS, patients, and providers. Contributory factors 
of the economic burden can be used by CMS in deriving risk-based cost estimates that are being 
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used in value-based reimbursement models. The possible association of ACO to CRN for 
developing targeted intervention to reduce CRN. Our cost estimates can also be used to evaluate 
cost-effectiveness of interventions of care for ACO patients. By examining the possible impact 
of medication type (ICS/LABA vs ICS) on medication adherence, our study findings can provide 
real-world evidence on adherence patterns.  
1.2 Innovation 
a) The present study will be a “series of firsts.” The study findings will fill a knowledge gap 
in the health outcomes of ACO in a nationally representative sample of the community 
dwelling Medicare beneficiaries in the US. For example, this is the first study to evaluate 
contributing factors to cost burden, CRN and long-term Medicare adherence among ACO 
patients.  
b) Leveraging data from nationally representative surveys and medical claims data, we are 
able to have the “best of both worlds”. The unique feature of MCBS-linked Medicare is 
the linkage between survey data and Medicare claims. In the survey component of the 
MCBS, the self-reported information not available in insurance claims databases (e.g. 
functional limitations, health status, smoking habit, and others). The Medicare claims 
component provides fee-for-service claims for both Part A and B. These claims include 
information on treatment, diagnosis, health services utilization, and Medicare payments49.  
c) Generate new knowledge that may be used to improve medication adherence by 
evaluating modifiable factors such as regimen complexity and the out-of-pocket cost 
burden on CRN.  
d) The application of advanced econometric and novel methods such as “group-based 
trajectory modeling” (GBTM). GBTM has been extensively applied in psychology, and 
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criminology, but very few studies evaluated medication adherence using GBTM. 
Longitudinal evaluation of adherence using GBTM can yield more useful classifications 
compared to traditional methods such as proportion of days of coverage (PDC). 
1.3 Specific Aims 
AIM 1: Estimate the excess economic burden of ACO (direct healthcare expenditures) and 
its contributory factors among older Medicare beneficiaries using post-regression 
decomposition techniques. 
Hypothesis: A majority of the excess economic burden of ACO can be explained by 
medication non-adherence, fragmented care, and the presence of other comorbidities. 
AIM 2:  Evaluate the adjusted association of ACO to CRN among older Medicare 
beneficiaries.   
Hypothesis: Older adults with ACO will be more likely to report CRN and this can be 
explained by medication regimen complexity and a high out-of-pocket (OOP) cost 
burden. 
AIM 3: Examine the impact of medication type (ICS vs ICS/LABA) on adherence over time 
among ACO patients who initiated maintenance therapy.   
Hypothesis: Adults with ACO who use ICS/LABA have poorer adherence to maintenance 
therapy over time. 
1.4 Approach 
Conceptual Framework 
 We adopted features from the Anderson Health behavior model50 to study all aims in this 
study (Figure 1).  This model has been used in many studies with different health conditions to 
study health care expenditures. According to this model, health care expenditure is determined 
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by five factors: (1) predisposing factors, (2) enabling factors, (3) need factors, (4) personal health 
practices, (5) external factors. Predisposing factors are those reflecting an individual’s propensity 
to use health services. These include factors like age, race/ethnicity, etc. Enabling factors are 
those that facilitate access to health care services. Examples of enabling factors include 
education status, health insurance coverage. etc. Need factors are potential needs for health 
services use, for example presence of comorbidities. Personal health practices factors reflect an 
individual’s lifestyle. These include factors such as smoking habits and obesity. External factors 
are those related to environmental factors (e.g. region of residency). 
Figure 1.1 
Conceptual Framework for Factors Associated with Healthcare Expenditures 
Adapted from Anderson’s Model 
 
Data Sources 
We will leverage multiple data sources to accomplish our research Aims. For Aims 1 and 2, 
we will use Medicare Current Beneficiary Survey (MCBS) linked to Medicare claims. For Aim 
3, we will use the 10% random sample of Optum Clinformatics Data Mart®. 
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MCBS  
The MCBS is a continuous, multipurpose survey of a nationally representative sample of the 
Medicare population, conducted by CMS. The MCBS is conducted on a representative sample of 
Medicare beneficiaries. The survey is repeated annually for three years51. All participants are 
interviewed in person or with computer-assisted personal interview technology. From 1991 to 
2013, the MCBS released two data files, the Access to Care (AC) and the Cost and Use (CU) 
annually, although the samples in both files share substantial overlap. The AC file can be linked 
to the CU file. Each year of the MCBS may be used for cross-sectional analyses or for 
conducting longitudinal analyses. We will use following files for Aims 1 and 2:  
MCBS - Access to Care (AC) Files: The AC files contain information on beneficiaries’ socio-
demographics, self-reported health status and conditions, health insurance coverage, medication 
adherence, and cost-related medication adherence. The AC files represent the “always enrolled,” 
Medicare beneficiaries. This file does not include survey-reported use of health care services and 
costs.  
MCBS – Cost and Use (CU) Files: The CU file is designed to provide a complete user file, 
and it uses an “ever enrolled” population. The “ever enrolled” population includes health care 
services and costs for all Medicare beneficiaries who joined the program during the year and 
those who died during the year. The CU file includes survey reports for services not included in 
Medicare billing files (e.g. prescription drugs). Moreover, for Medicare covered services, the 
accuracy of service types, payments, and sources of payment has been improved by using an 
extensive operation to match and reconcile survey reports and Medicare bills.  
MCBS – Medicare Claims Files: The CU and AC files can be linked to Medicare Fee-for-
Service claims data. This will provide a unique opportunity for researchers to obtain a 
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comprehensive picture of health services received, sources of payment, amounts paid, and 
including payments which are not covered by Medicare49. Medicare claims files include all Part 
A and B claims files. However, there is no separate file for Part D events. Information about 
prescription medications are is available in Prescribed Medicine Event (PME) file within the CU 
file. 
10% Random Sample of Optum Clinformatics Data Mart® 
This database provides a nationally representative source of data on inpatient, outpatient and 
pharmacy claims, lab results, and some demographic characteristics. This dataset is a 10% 
random sample of health insurance claims from approximately 47 million individuals, 80% of 
whom were insured through their employment52. Data are available for periods between January 
2007 and October 2017. We will use available data from October 2007 to October 2017.  
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CHAPTER 2  
2 Economic Burden of Asthma- Chronic Obstructive Pulmonary Disease Overlap (ACO) 
among Older Adults in the United States 
2.1 Abstract 
 The objectives of this study are to estimate the excess economic burden of Asthma-
Chronic Obstructive Pulmonary Disease Overlap (ACO) among older adults in the United States 
and to evaluate the extent to which group differences in patient-level characteristics contribute to 
this excess economic burden. We used a cross-sectional study design with data from a nationally 
representative survey of Medicare beneficiaries (Medicare Current Beneficiary Survey) linked to 
Medicare fee-for-service claims. Economic burden was measured by total, third-party healthcare 
expenditures and patients’ out-of-pocket spending (i.e. spending more than 10% of income on 
healthcare).  Generalized Linear Models (GLM) and post-regression linear and non-linear 
decomposition methods were used to analyze the excess economic burden of ACO. Older adults 
with ACO had unfavorable profiles including a higher number of prescription medications 
utilized (mean 16.12+7.27 vs. 7.53+5.32) and increased levels of fragmented care (78.08+12.01 
vs. 66.80+22.17). Older adults with ACO had higher average total healthcare expenditures 
($45,532 vs. $12,743) and higher out-of-pocket spending burden (19% vs. 8.5%) compared to 
those without asthma or COPD.  Multivariable regression models indicated that the adjusted 
associations of ACO to economic burden remained positive and statistically significant. Nearly 
three-quarters of the excess total healthcare expenditures and 83% of the out-of-pocket spending 
burden were explained by differences in predisposing, enabling, need, personal healthcare 
practices, and external factors among the two groups.  The higher number of unique medications 
and the increased incidence of fragmented care were the leading contributors of the excess 
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economic burden among older adults with ACO.  Interventions that reduce number of 
medications and fragmented care have the potential to reduce the excess economic burden 
among older adults with ACO.     
2.2 Introduction 
In the United States (US), chronic obstructive respiratory disease in older individuals occurs 
most often as COPD or asthma53. Among 15–45% of older adults initially diagnosed with COPD 
or asthma, can later develop “Asthma-COPD overlap” (ACO) with symptoms consistent with 
each disease state 9. A significant disease burden and adverse health consequences exist for ACO 
patients compared to patients with either asthma only or COPD only. Prior research suggest that 
ACO patients experience higher acute respiratory events, outpatient visits, and hospitalizations 
compared to those with either asthma only or COPD only12,13,53. The prevalence rates of  
comorbid medical conditions and polypharmacy are also higher in ACO compared to either 
asthma or COPD14, suggesting that adults with ACO may constitute a significant economic 
burden. 
However, current estimates of the economic burden of ACO in older adults are unknown. 
There have been only two studies in the US on the economic burden of ACO. The first study was 
conducted among enrollees of Medicare Advantage Plan in 2004. This study found that the 
average annual healthcare expenditures for the patients with ACO is higher than patients with 
COPD only18. The second study was a retrospective commercial claims analysis which reported 
that healthcare expenditures were twice as high for patients with ACO compared to those with 
asthma only between 2007-201017. Neither of these studies provided any information on average 
total healthcare expenditures, out-of-pocket (OOP) expenditures, and high OOP spending burden 
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of older adults with ACO or compared economic burden with those who had no-asthma no-
COPD (NANC). 
Estimating the excess economic burden of ACO is important for several reasons. First, 
there is an emerging focus on achieving optimal healthcare with the triple aims of better health, 
higher quality, and lower costs54. For reducing overall healthcare costs, identification and 
management of high-cost conditions are very important55.  Second, reducing costs also requires 
innovative practice models and payment reforms 56. For example, innovative payment models 
such as bundled payments for episodes of care need critical information on high-cost individuals 
as part of  case mix adjustments 57. Third, estimating the excess  economic burden can provide 
benchmarks for  deriving cost-effectiveness of targeted interventions for management of ACO58. 
Finally, estimating the economic burden of ACO can translate disease burden into a universal 
metric (i.e. monetary value) which can be used for decision making by payers, policymakers, and 
other stakeholders 59.  
In addition to excess economic burden, it is important to assess the high OOP spending 
burden because this can lead to poorer health-related behavior (e.g. poor medication 
adherence)60, poorer health outcomes, and increased future expenses61. High OOP spending 
burden is quite common among the older adults in the US. Although many older adults have 
health insurance coverage through Medicare, not all services are fully covered. This leaves many 
individuals paying for their healthcare through OOP payments. A study of older adults conducted 
by West Health and Gallup reported that the older adult population spent nearly $22 billion from 
their savings to pay for healthcare, suggesting that older individuals may not have the financial 
resources to manage their health when they need it the most62. It has to be noted that nearly a 
quarter of Medicare beneficiaries have less than $15,000 in total savings63. Although we do not 
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have estimates of OOP payments among ACO patients, existing literature on OOP spending 
burden of either COPD or asthma suggest that OOP spending can be substantial.  For example, 
the annual OOP costs of a single COPD inhaler per month was estimated to be about $900 under 
a standard 2015 Part D plan64. 
Although quantifying excess economic burden of ACO can provide needed information 
for decision making, it may not provide enough information to act on because costs are 
influenced by many factors including severity, care fragmentation65, age66, and presence of other 
chronic conditions.67  Similarly, high OOP spending burden is affected by many patient-level 
characteristics (e.g. age68, comorbidities69, income level70). Understanding the extent to which 
differences in patient-level factors drive the excess economic burden and high OOP spending 
burden of ACO is vital to case-mix adjustment, allocation of resources, payment reforms, cost-
sharing, and cost reduction efforts.  
Therefore, the main objectives of this study are to quantify the economic burden of ACO 
using data from a nationally representative sample of Medicare beneficiaries, and estimate the 
extent to which differences in characteristics among patients with ACO and NANC explained 
this economic burden.  
2.3 Methods 
Study Design  
This study used a cross-sectional study design by using data from multiple years of linked 
fee-for-service Medicare claims with a nationally representative survey of Medicare 
beneficiaries.   
Data Source 
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This study used the Medicare Current Beneficiary Survey (MCBS) linked to fee-for-service 
Medicare claims from 2006 through 2013. The MCBS is a rotating four-year panel survey of a 
nationally representative sample of individuals enrolled in Medicare Part A and B. The survey 
data sources provide information on direct medical costs, sources of payment, OOP payments, , 
health outcomes, clinical diseases, and sociodemographic of beneficiaries51. To improve the 
completeness and accuracy of medical costs and utilization,  survey data are matched with fee-
for-service Medicare claims for making best of both claims and survey data worlds49. For this 
study, we used Medicare claims files for capturing information on health conditions and third-
party payments.  We also used “Cost and Use” (CU) survey files for deriving OOP burden and 
other variables (e.g. sex, age, race, prescription coverage, education level, disability status, 
smoking habit, and residency region). 
Study Sample  
The final analytical sample consisted of 38,089 person years and included community-
dwelling Medicare beneficiaries, 65 years or older, alive throughout the calendar year, and 
enrolled in both Parts A and B fee-for-service during the calendar year. (Appendix 7.1) 
Measures 
Dependent Variables:  Economic Burden  
Total HealthCare Expenditures  
 All expenditures information in MCBS linked to Medicare claims files was extracted 
through a reconciliation process by combing survey information and Medicare claims files51. 
Linking these files provide a unique opportunity of cost analyses on the Medicare population 
compared to using either survey data or claims data alone49. Respondents to survey utilized 
calendars to record their medical events and were asked to save all their receipts from insurance 
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companies, their receipts, and prescription bags provided by the pharmacy. Total healthcare 
expenditures were calculated by adding all the expenditures for inpatient visits, outpatient visits, 
prescription drugs, medical provider services, dental services, and other medical services. 
Sources of payment included both third-party expenditures and out-of-pocket (OOP) 
expenditures.  
Third-party Expenditures  
The third-party payers in this study included Medicare, Medicaid, private insurances, 
Veterans Affairs Health insurance, and other payers.  We calculated third-party expenditures by 
subtracting OOP payments from total healthcare expenditures.  To account for inflation of 
medical services, all the expenditures were converted to 2013-equivalent US dollars, by using 
the annual consumer price index of medical services 71.  
High OOP Spending Burden of Individuals and Families  
OOP expenditures in the MCBS represented amount spent by the patients or their 
families on healthcare, but not include insurance premium. To capture OOP expenditures, 
respondents of the MCBS were asked to record all the details of what they spent on healthcare 
bills and what they expected to spend on additional bills51. Respondents also reported their 
household income. OOP spending burden” was calculated as the ratio of OOP to income. Older 
adults who spent more than 10% of their income on healthcare, were classified as having high 
OOP burden.  
Spending more than 10% of income on healthcare may compromise essential living 
expenses such as housing and food.  As there is no consensus on the definition of OOP burden, 
we chose the 10% threshold based on previously published literature which reported that this 
threshold is above generally accepted affordability standards61,72.  
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Key Independent Variable: Asthma/ COPD categories   
 The key independent variable of this study was asthma/COPD categories. Individuals 
with either asthma or COPD were identified by using the International Classification of Diseases, 
9th edition diagnostic codes available in fee-for-service Medicare claims (Appendix 7.2).  We 
used inpatient, outpatient, physician, skilled nursing home, and home healthcare claims. The 
diagnosis codes for identification of asthma and COPD cases have been used in previously well-
designed published research73,74. Individuals with a minimum of two outpatient visits (14 days 
apart) or one inpatient visit for asthma were considered to have asthma.  Older adults with one 
inpatient or two outpatient visits (14 days apart) for COPD were categorized as individuals with 
COPD. Based on the presence of asthma or COPD, we created the following four asthma/COPD 
categories: 1) Asthma COPD Overlap (ACO); 2) Asthma only; 3) COPD only; and 4) No 
Asthma no COPD (NANC). 
Other independent variables 
The selection of other independent variables that could affect expenditures were derived 
from published literature 75,76 and guided by Andersen’s Healthcare Behavioral Framework 50. 
Based on the model, the healthcare outcomes (in our study total healthcare expenditures) is 
affected by predisposing (age, sex, and race), enabling (marital status, education level, poverty 
status, prescription coverage, and fragmented care), need (number of chronic conditions, number 
of activities of daily living (ADL), and number of unique medications) factors, personal 
healthcare practices (obesity and smoking status) and external environment (e.g. residency 
region). For this study, the number of chronic conditions included cancer, diabetes, hypertension, 




Patient characteristics by asthma/COPD categories were compared using chi-square test 
for categorical variables and ANOVA for continuous variables. The unadjusted and adjusted 
associations of asthma/COPD categories to economic burden were evaluated using generalized 
linear models (GLM). GLM with a gamma distribution and log-link function was used for total 
and third-party expenditures and GLM with binomial distribution and log-link function (i.e. 
logistic regression) was used to model high OOP burden. The robust estimates of excess burden 
of ACO were derived using the counterfactual recycled prediction. Separate models were used 
for total healthcare expenditures, third-party expenditures, and OOP expenditures. In all the 
models, the reference group was NANC. In the adjusted models, we controlled for predisposing, 
enabling, need factors, personal healthcare practices, and external environmental factors.  
To estimate the extent to which differences in characteristics of individuals among the 
four groups (ACO, asthma only, COPD only, and NANC) contribute to the excess economic 
burden we used linear and non-linear decomposition analyses.  In these analyses, we distinguish 
between explained and unexplained parts of the average difference in an outcome (example: total 
healthcare expenditures). The explained part was derived by taking the differences in average 
characteristics between two groups and weighting by regression co-efficient estimates from the 
pooled regression of fully adjusted model.  Unexplained portion was derived from differences in 
regression-coefficients of the two groups weighted by average characteristics of groups.  
Linear decomposition analysis followed the Blinder-Oaxaca approach for survey data 
using pooled regression weights. The decomposition analysis used log-transformed total 
healthcare expenditures as the dependent variable and assesses how much of the difference in 
log-transformed total healthcare expenditures between groups can be due to difference in 
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characteristics (e.g. the predisposing, enabling, need, personal healthcare practices, and external 
environmental factors described above).  For high OOP burden, we used the non-linear 
decomposition technique proposed by Fairlie79. We summarize results from the decomposition 
analysis by comparing NANC to: 1) ACO; 2) COPD only and 3) asthma only. All data 
management and analyses were conducted with SAS 9.4 (SAS Institute Inc., Cary, NC) and we 
used Stata 14 (StataCorp LLC, College Station, TX) for decomposition analyses.  
2.4 Results 
 Sample Description 
 The study sample consisted of 38,089 person-years and included community-dwelling, 
full-year enrolled in fee-for-service Parts A and B, elderly (age > 65 years) Medicare 
beneficiaries. (Appendix 7.3) The prevalence of ACO, asthma only, COPD only conditions were 
1.5%, 2.4%, and 8.8% respectively between 2006 and 2013. ACO, asthma only, COPD only and 
NANC groups were significantly different in terms of all predisposing, enabling, need, personal 
healthcare practices, and external factors (Table 2.1).  For example, individuals with ACO had 
the highest rates of poverty (59.8% vs 44.2%) and higher levels of fragmented care (78.08+ 
12.01 vs 66.08+ 22.17) and higher number of unique medications (16.12 + 7.27 vs 7.53+ 5.32) as 
compared to NANC.   
Healthcare Expenditures 
The unadjusted and adjusted average annual total healthcare and third-party expenditures 
are provided in Figure 1. Average total, third-party and OOP expenditures were significantly 
higher for all Asthma/COPD categories compared to NANC. Medicare beneficiaries with ACO 
in comparison with NANC had almost 3.5-time higher unadjusted annual average total 
healthcare expenditures ($45,532 vs. $12,743), with an excess per patient cost of $32,789 (P 
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<0.001).  The excess total healthcare expenditures COPD only and asthma only were $17,409 
and $10,760 respectively.  The excess third-party expenditures for ACO, COPD only and asthma 
only were: $31,113, $16,383, and $9,459 respectively. Similar differences were observed in OOP 
payments (Figure 1).  
Using recycled prediction, we observed that annual total healthcare expenditures 
remained significantly higher (Figure 2.1-b) for those with ACO ($22,968), yielding an excess 
cost of $7,211 (P <0.001). Adjusted annual third-party payers’ expenditures were significantly 
higher ($6,871) for individuals with ACO as compared to NANC.  Compared to older adults 
with asthma only, individuals with ACO had an excess total healthcare expenditure of $11,505 
(P <0.001) and third-party payers’ expenditures of $11,351 (P <0.001). Moreover, individuals 
with ACO had $6,504 (P <0.001) excess total healthcare expenditures and $6,273 (P <0.001) 
higher third-party payers’ expenditures in comparison with those with COPD only.  
Results from the linear decomposition analysis are summarized in Table 2. The average 
predicted log-transformed total healthcare expenditures for the ACO group was 10.393 units; the 
corresponding figure for NANC was 8.994 units, yielding a difference of 1.399 log-transformed 
expenditures. We found that differences in predisposing, enabling, need, personal healthcare 
practices, and external factors could explain 77% of this difference in average log-transformed 
total healthcare expenditures. Thus, if older adults with ACO were to have similar characteristics 
as those with NANC, the difference in log-transformed dollars would reduce to 8.99. Of the 
1.399 unit difference, 1.081 units (76.98%) were explained by the differences in characteristics. 
The number of unique medications (0.833 units, 77.30%) and fragmented care (16.08 units, 
14.93%) were explained by differences in other characteristics.  
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Of the total difference in log-transformed costs (1.003) among COPD only and NANC 
group, 0.594 units (or 59.21%) was explained by differences in the patient-level characteristics 
between the two groups. Similarly, of the total difference in log-transformed expenditures 
(0.735) among asthma only and NANC group, 0.655 units (89.21%) was explained by 
differences in characteristics between asthma only and NANC groups. In all these comparisons, 
number of unique medications, need factors (i.e. number of chronic conditions and number of 
ADL) and fragmented care were the leading drivers of the excess economic burden.  
High OOP spending burden 
Figure 3.2 summarizes the prevalence of high OOP spending burden among the four 
asthma/COPD groups; 42% with ACO, 34% with COPD and 29% with asthma reported high 
OOP burden as compared to 17% among individuals with NANC. In the unadjusted logistic 
regression models, the odds of high OOP spending burden was significantly higher among 
individuals with ACO (UOR = 3.51, 95% CI = [2.96, 4.16], P<0.001), asthma only (UOR = 1.99, 
95% CI = [1.68, 2.36], P<0.001), and COPD only (UOR = 2.40, 95% CI = [2.20, 2.61], P<0.001) 
as compared to the NANC group. In the adjusted logistic regression models, the association 
remained significant. The odds of high OOP spending burden was significantly higher among 
individuals with ACO (AOR = 3.51, 95% CI = [2.96, 4.16], P<0.001) and COPD only (AOR = 
3.51, 95% CI = [2.96, 4.16], P<0.001) as compared to the NANC group.  
Based on non-linear decomposition analysis, we found that of the 23.53 percentage point 
difference in high OOP burden, 19.59 percentage points were explained by the differences in the 
characteristics between the ACO and the NANC group (Table 2.2).  Thus, if older adults with 
ACO were to have similar characteristics as those of the NANC group, the difference in OOP 
burden would be reduced to 18.5 percentage points.  Of this total difference, 13.18 percentage 
 25 
points (or 67.29%) was explained by the number of unique medications. Similar findings were 
observed when asthma only group was compared to NANC and the COPD only group was 
compared to NANC.   
2.5 Discussion 
This study examined the excess economic burden associated with ACO among older 
adults in the US, using multiple years of a nationally representative sample of Medicare 
beneficiaries.  In this study, the overall prevalence of ACO was 1.5%. Although no study has 
reported the specific prevalence of ACO among Medicare beneficiaries, this estimate is less than 
the 3.8% which was previously reported by Kumbhare et al for (65-85 years old) older adults in 
the United States14. Possible explanations of this difference are methods of identification and 
time period. While this study used fee-for-service Medicare claims for identification of ACO 
during a calendar year, Kumbhare et. Al. used “ever diagnosed” using self-reports.  Thus, we 
may have captured only older adults who had currently active asthma and COPD and had 
diagnoses updated in their medical claims.  
In terms of projected total healthcare expenditures, nearly two billion dollars (2013USD) 
was spent on the healthcare of older community-dwelling adults with ACO (weighted number of 
ACO adults in 2013= 42,984 multiplied by the average per-capita cost $45,532). In terms of the 
excess economic burden, individuals with ACO had almost four, two, and 1.5 times higher 
expenditures compared to individuals with NANC, asthma only, and COPD only, respectively. 
Even after controlling for multiple determinants of expenditures, the presence of ACO was 
associated with significantly higher expenditures in comparison with individuals with NANC, 
asthma only, or COPD only, consistent with previously published studies that compared per-
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capita expenditures of individuals with ACO to those with asthma only17 or those with COPD 
only18.  
The excess expenditures associated with ACO is not surprising because studies have 
documented increasing expenditures with increasing number of chronic conditions80. 
Furthermore, our finding that ACO patients had higher economic burden compared to those with 
asthma only or COPD only may be explained through higher rates of uncontrolled disease states, 
respiratory infections, and exacerbations, which may lead to higher expenditures.  While 
healthcare utilization and reasoning for expenditure was not directly reviewed in this study, a 
prior study of 17,088 COPD patients in Taiwan reported that ACO patients experienced almost 
twice as many acute respiratory events (e.g. acute respiratory failure, pneumonia, and acute 
exacerbation) than did the rest of the COPD cohort12.  This higher event rates undoubtedly lead 
to higher healthcare resource utilization and overall higher direct costs. 
In this study, those with ACO had higher odds of high OOP spending burden compared 
to all other groups in both unadjusted and adjusted models.  This high burden could be due to 
cost-sharing of Medicare-covered services, including prescription drugs and payments for non-
covered services by Medicare.  OOP burden may be particularly high among individuals with 
ACO because of historically high cost-sharing of inhaler medications.  Based on data from 
nationwide Part D plans, it has been estimated that mean OOP expenditures were $30–$105 per 
inhaler in 201564. According to this study, a typical older Medicare beneficiary who use 2-3 
inhalers per month have annual OOP expenditures of at least $1,622–$2,81l for their inhalers.  
Individuals with ACO may have greater need for some of the services not covered by 
Medicare compared to NANC as they are higher risk of these conditions. For example, 
individuals with ACO have significantly higher odds (AOR = 1.82, 95% CI = [1.59, 2.08], 
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P<0.001) of removing all teeth compared to NANC81, suggesting greater spending on oral 
healthcare by patients.  It has also been reported that COPD patients are vulnerable to low-value 
care82, which may increase OOP spending of families and patients through cost-sharing.  
Medicare reform proposals that focus on value-based healthcare that balance the value of health 
services to the OOP spending burden of patients (vs. quantity of care) may reduce the excess 
economic burden of patients. 
The current study used linear and non-linear decomposition analyses to examine the excess 
economic burden of chronic respiratory conditions, one of the top four conditions of public health concern 
designated by the World Health Organization (WHO)83. The other three conditions are cardiovascular 
disease, diabetes, and cancer.  It is important to note that older adults with chronic respiratory conditions 
also have higher rates of CVD, diabetes, and cancer. A population survey among (>18 years) adults in the 
US also found that the adjusted odds of six chronic conditions (e.g. cardiovascular diseases, diabetes, and 
depression) is higher in ACO compared to asthma only and COPD only 14. In our study, 91% of ACO 
patients had more than two other chronic conditions which was higher than asthma only (89%), COPD 
only (87%) and NANC (76%) groups. Our decomposition analysis suggested that patient-level 
characteristics such as higher number of co-existing chronic conditions and related characteristics (i.e., 
higher number of unique medications and higher levels of fragmented care) were the leading drivers of 
the excess economic burden among ACO patients. For example, receiving care from several different 
providers often results in gaps in communication between providers which can lead to suboptimal care 
and polypharmacy75,84. Prior studies suggest that more fragmented care is associated with more diagnostic 
tests, more low-value care, and lower patient satisfaction85–87.  Previous studies further suggest the 
associations of fragmented care and higher number of emergency department (ED) visits, higher 
hospitalization rates, and higher expenditures77,88. 
Taken together, our study findings highlight the need for a “holistic management” of older adults 
with chronic respiratory conditions, specifically ACO, asthma, and COPD.  Given that those with chronic 
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respiratory conditions may need to see multiple providers and have a high medication burden, the risks of 
fragmented care and drug-disease and drug-drug interactions are very high. These factors often lead to 
greater economic burden, as evidenced by our study. Although the CMS began reimbursing providers for 
providing coordinated care for those with multiple conditions in 201589, it remains to be seen whether 
such fiscal incentives for care coordination have resulted in less fragmented care and reduced healthcare 
expenditures. In this context, patients with chronic respiratory conditions (ACO, asthma, and COPD) may 
need to be managed in a patient-centered medical home model which focuses care that is “comprehensive, 
team-based, coordinated, accessible, and focused on quality and safety.” 90. As documented in published 
literature, pharmacists can play an important role in medical homes by reducing unnecessary medications, 
counseling patients and/or caregivers, reviewing medication regimens and inhaler techniques, and 
completing adherence assessments91–93. Such management may improve not only outcomes but also lower 
the economic burden of patients, payers, and health systems.  
Summarily, our findings have policy and program implications. Our study findings highlight the 
need to develop guidelines for the management of overlapping chronic conditions. Applying “single-
disease focused” clinical practice guidelines can result in missing or inappropriate therapies and adverse 
drug-drug and drug-disease interactions. A systematic review of recommendations in 12 UK national 
clinical guidelines notes that potentially serious drug-drug interactions were common94. Adherence to 
guidelines intended for single-diseases in those with multiple chronic conditions can also generate more 
low-value care and lead to higher healthcare expenditures the patient, payors, and the society as holistic, 
big-picture care may be lacking 95,96.  
2.6 Limitation 
As with most studies, this study also had some limitations. The first limitation was the 
lack of availability of data from recent years. Notwithstanding this limitation, we used the most 
recently available data of a nationally representative large sample of elderly Medicare 
beneficiaries. Another limitation was the lack of information on the onset and severity of 
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diseases. To overcome this, we used ADL status as a proxy of overall severity of diseases. 
Furthermore, the findings of the current study cannot be generalizable to all older adults in the 
US, although it is generalizable to the majority of older adults (community-dwelling Medicare 
beneficiaries enrolled in fee-for-service Part A and B). 
2.7 Conclusion 
This study is the first to document the excess economic burden of ACO among elderly 
Medicare beneficiaries. ACO among elderly Medicare beneficiaries was associated with 
substantial total healthcare expenditures, third-party payers’ expenditure and high OOP spending 
burden, even after adjusting with a comprehensive list of variables. Post regression 
decomposition analyses revealed that the challenges associated with multiple chronic conditions, 
specifically use of multiple medications and high levels of fragmented care were the leading 
drivers of the excess economic burden. Individual, policy, and program interventions that 
facilitate coordination of care may reduce the excess economic burden of older adults with 





Note:  Based on 38,089 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in 
fee-for-service Part A and Part B during the calendar year and alive during the calendar year.  
Significant group differences in asthma-COPD status were based on Rao-Scott chi-square tests. ANOVA test was used for number of 
unique medications and % fragmented care. 
Table 2.1. 
Unweighted N and Weighted Percentages of Characteristics by Asthma /COPD Categories (Column %) 
Older (age > 65 years) Medicare Beneficiaries   








  N Wt. % N Wt. % N Wt. % N Wt. %  
ALL 589 1.5 860 2.4 3,518 8.8 33,122 87.3  
Sex         *** 
 Female  389  67.0 658 77.6  1,719  49.7  18,703  56.1  
 Male  200  33.0 202 22.4  1,799  50.3  14,419  43.9  
Age in Years         *** 
 65-74  205  39.5 397 53.7  1,215  40.9  13,290  48.1  
 75-84  270  44.1 323 34  1,642  43.7  13,413  36.8  
 85 and above  114  16.4 140 12.3  661  15.4  6,419  15.1  
Race/Ethnicity         *** 
 White  451  76.7 663 78.3  3,044  86.7  27,371  82.6  
 Black  47  8.0 85 9.5  168  4.7  2,303  6.8  
 Latino  48  7.6 60 6.5  146  4.0  1,891  5.9  
 Other race  42  7.7 52 5.7  153  4.6  1,486  4.8  
Marital Status         *** 
 Married  224  39.3 405 48  1,690  49.3  17,456  55.2  
 Not married  364  60.7 454 52  1,824  50.7  15,656  44.8  
Education          
 Less than high school  194  31.6 178 19.3  1,150  31.7  7,734  21.3 *** 
 High school  218  37.8 287 31.3  1,284  36.4  11,962  35.6  
 Above high school  175  30.6 393 49.4  1,072  31.9  13,295  43.1  
Poverty Status         *** 
 Less than 200% FPL  364  59.8 415 44.9  2,077  57.7  15,526  44.2  
 At least 200% FPL  225  40.2 445 55.1  1,441  42.3  17,596  55.8  
Prescription Coverage         *** 
 Yes  414  70.6 590 67.0  2,299  65.2  20,397  60.9  
 No  175  29.4 270 33.0  1,219  34.8  12,725  39.1  
% Fragmented Care  78.08† 12.01‡ 75.06† 14.65‡ 73.88† 16.62‡ 66.80† 22.17‡ *** 
# Other Chronic Conditions         *** 
 0-1  53  9.0 93 11.0  419  13.0  7,122  23.6  
 2-3  273  47.6 471 56.4  1,754  50.7  17,539  53.4  
 4-6  250  43.3 285 32.6  1,272  36.3  8,035  23.0  
# ADL         *** 
 0  269  45.4 544 64.5  1,830  52.8  23,532  73.4  
 1-2  192  34.0 213 25.0  1,096  31.0  6,683  19.0  
 3-6  123  20.6 102 10.5  573  16.2  2,793  7.6  
# Unique Medications 16.12† 7.27‡ 12.73† 6.29‡ 12.57† 6.75‡ 7.53† 5.32‡ *** 
Obesity         *** 
 Yes 207 38.5 298 36.5 897 26.8 7597 24.0  
 No 381 61.3 550 62.1 2588 72.2 25207 75.0  
Smoking Habit         *** 
 Current/Past 429 73.7 410 48.7 2943 84.4 18256 56.0  
 Never 154 25.3 449 51.2 556 15.0 14762 43.7  
Residency Region         *** 
 Northeast  118  23.3 170 22.6  578  17.9  5,115  17.3  
 South  126  20.4 189 21.8  873  23.8  8,321  23.9  
 Midwest  250  39.5 355 38.3  1,668  46.3  14,104  40.3  
 West  95  16.9 146 17.4  399  11.9  5,582  18.4  
 31 
ADL: Activities of Daily Living; FPL: federal poverty level; N: unweighted number; Sig: significance; Wt: weighted; %: Percentage; 
†: Mean; ‡: Standard Error; ***p<.001, ; **.001 ≤ p < .01; *.01 ≤ p <.05
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Figure 2.1. 
Total Healthcare Expenditures and High Out-of-Pocket Burden by Asthma/ COPD Categories 
Older (age > 65 years) Medicare Beneficiaries 
Medicare Current Beneficiary Survey, 2006-2013 
 
Note (a) Unadjusted expenditures, (b) Adjusted expenditures from recycle prediction” group, (c) high OOP spending burden percentage 
(d) Unadjusted and adjusted odds ratio of high OOP spending burden by asthma/COPD categories  
Based on 38,089 elderly Medicare beneficiaries who were observed between years 2006 and 2013. The variables in the adjusted models 
were selected based on Andersen’s healthcare behavioral model and include sex, age, race, marital status, poverty, education,  
prescription coverage, fragmented care, # ADL, # chronic conditions, # unique medications, overweight, smoking habit, and residency 
region.  
Abbreviations: ADL: Activity Daily Limitation; COPD: chronic obstructive pulmonary disease; OOP: Out-of-Pocket; Log: natural 
logarithm; #: number; $: Dollar; %: Percentage; +: Excess cost comparing to no-asthma no-COPD;
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Table 2.2 
Post-Regression Decomposition Analyses  
Older (age > 65 years) Medicare Beneficiaries 
Medicare Current Beneficiary Survey, 2006-2013 
Decomposition of Log Total Healthcare Expenditures (2013US$) by Asthma/COPD Categories  
by Using Blinder Oaxaca Liner Decomposition analysis for survey Data using Pooled Regression Weights 
 Asthma COPD Overlap Asthma Only COPD Only 
Average Log Total Healthcare Expenditures 10.3935 9.7287 9.9944 
Average Log Total Expenditures of “neither asthma nor COPD” group 8.9941 8.9941 8.9940 
Difference in Log Total Healthcare Expenditures 1.3994 0.7346 1.003 
Total “explained” percentage 76.98% 89.21% 59.21% 
% Contribution to the “Explained” Portion 
 Asthma COPD Overlap Asthma Only COPD Only 
Predisposing characteristics (sex, age, race) -1.51% -6.28% 3.17% 
Enabling factors 1 (marital status, poverty, education, prescription coverage) -2.00% 1.18% -3.70% 
Enabling factor 2 (fragmented care) 14.93% 18.04% 19.58% 
Need Factors 1 (# ADL, # chronic conditions) 11.84% 7.16% 15.16% 
Need Factors 2 (# unique medications) 77.30% 79.60% 66.52% 
Personal healthcare practice (obesity, smoking) -0.85% -1.64% 0.08% 
External factors (residency region) 0.29% 1.94% -0.81% 
Decomposition of High OOP spending burden by Asthma/COPD Categories 
by Using Fairlie’s Non-Linear Decomposition for Weighted Data 
 Asthma COPD Overlap Asthma Only COPD Only 
Probability of having high OOP spending burden 0.4204 0.2925 0.3336 
Probability of having high OOP spending burden of “neither asthma nor COPD” 
group 0.1850 0.1850 0.1850 
Differences in probability of high OOP spending burden 0.2353 0.1075 0.1486 
Total “explained” percentage 83.24% 89.17% 71.67% 
% Contribution to the “Explained” Portion 
 Asthma COPD Overlap Asthma Only COPD Only 
Predisposing characteristics (sex, age, race) -1.40% -2.80% -0.41% 
Enabling factors 1 (marital status, poverty, education, prescription coverage) 15.97% 3.45% 20.26% 
Enabling factor 2 (fragmented care) 5.65% 8.54% 5.96% 
Need Factors 1 (# ADL, # chronic conditions) 11.55% 6.94% 11.73% 
Need Factors 2 (# unique medications) 67.29% 82.72% 62.64% 
Personal healthcare practice (obesity, smoking) 0.21% -0.30% 0.55% 
External factors (residency region) 0.73% 1.46% -0.74% 
Notes: Based on 38,089 felderly Medicare beneficiaries who were observed between years 2006 and 2013. The percent differences of domains of Andersen’s healthcare behavior 
model are illustrated in the model.  
Abbreviations: ADL: Activities of Daily Living; COPD: chronic obstructive pulmonary disease; OOP: Out-of-Pocket; Log: natural logarithm; #: number; $: Dollar; %: 
Percentage. 
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CHAPTER 3  
3 Asthma-Chronic Obstructive Pulmonary Disease Overlap and Cost-Related Medication 
Nonadherence among Older Adults in the United States 
3.1 Abstract 
Objective: Cost-related medication non-adherence (CRN) can negatively impact health 
outcomes in older adults with asthma-chronic obstructive pulmonary disease (COPD) overlap 
(ACO) by reducing access and adherence to essential medications. The objective of this study is 
to examine the association of ACO to any CRN and specific forms of CRN among a nationally 
representative sample of older (age > 65 years) adults.  
Methods: We adopted a cross-sectional study design using data from pooled cross-sectional 
Medicare Current Beneficiary Surveys (2006-2013) and linked fee-for-service Medicare claims. 
Unadjusted and adjusted logistic regressions that accounted for the complex survey design 
examined the association of ACO to any CRN and specific forms of CRN.  
Results: Among older adults with ACO, 16% reported any CRN.  The most common form of 
CRN was “failing to get prescription”. As compared to older adults with no asthma and no 
COPD, those with ACO were more likely to report any CRN (AOR = 1.50, 95%CI= [1.14, 
1.96]) and all forms of CRN. However, when the number of unique medications were added to 
the model, there were no statistically significant differences in CRN between the two groups.   
Conclusions: Older adults with ACO represent a vulnerable population with increased risk for 
CRN.  Multiple factors can contribute to CRN including: a higher number of prescribed 
medications, multiple co-morbidities, and cost of therapies.  Deprescribing – as appropriate – is 
an opportunity and process which could reduce the risk of CRN among the older Medicare 
beneficiaries with ACO. 
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3.2 Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are the two most common respiratory 
diseases worldwide.  Combined, more than 435 million adults suffer from asthma and COPD1,2.  In many 
cases where airway obstruction is noted, asthma and COPD can coexist as “Asthma-COPD overlap” 
(ACO), which can be as high as 50% among elderly  (age > 80 years) patients with either asthma or 
COPD10. Treatment for both asthma and COPD focuses on symptom management rather than clinical 
cure; similarly, ACO is managed with pharmacotherapy recommended in both disease states.  Adherence 
is critical in ACO as therapy is primarily maintenance therapy (i.e. taken daily) versus as needed to 
maximize effects on reducing inflammation, bronchoconstriction, and sputum production.  20,97. However, 
studies demonstrate many individuals with either asthma or COPD do not adhere to prescribed 
medication regimens with non-adherence rates often >20%26,29,30. While many factors influence 
medication adherence, older adults with chronic conditions often report cost-related barriers as a reason 
for medication nonadherence 98–102. High out-of-pocket (OOP) prescription costs can overwhelm some 
older adults compelling them to adopt cost-coping strategies103 such as (1) failing to fill a prescription; (2) 
delaying filling prescriptions; (3) skipping medication doses; and  (4) using  less than prescribed doses of 
a medication104.   
Although there are no published studies on cost-related non-adherence (CRN) among older adults 
with ACO, it is expected that ACO individuals may be particularly vulnerable to CRN based on studies 
focusing on either asthma or COPD.  In a 2004 study of disease-specific rates of CRN by Piette et al105, 
asthma and COPD were among diseases with the highest rates of CRN.  Castaldi et al estimated that over 
one third of older adults with chronic pulmonary diseases reported CRN32.  However, this study did not 
compare the risk of CRN for different types of chronic pulmonary diseases including ACO.   
Insight into the association of CRN to ACO is important because CRN has downstream effects and 
can lead to higher healthcare utilization76, morbidity98, and mortality106.  Information on contributors to 
CRN among adults with ACO can be used to develop a portfolio of programs targeting these contributors 
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and subsequently help improve adherence and reduce the risk of mortality and morbidity among older 
adults with ACO.  
 Therefore, our primary objective was to assess the association of ACO to CRN as compared to 
no-asthma and no-COPD and explore the factors that may affect the association of ACO to CRN among 
older adults (age > 65 years), using a nationally representative sample of Medicare beneficiaries  in the 
US. 
3.3 Methods  
Study Design  
We adopted a cross-sectional study design with data from the annual Medicare Current 
Beneficiary Survey (MCBS) from 2006 through 2013.  
Data Source  
The data sources for this study were the Medicare Current Beneficiary Survey (MCBS) and 
fee-for-service Medicare claims that are linked to the survey respondents. The MCBS is a 
rotating panel survey of a nationally representative sample of the Medicare population and has 
been carried out since 1991. The goals of the survey are to collect information on healthcare 
access, expenditures, sources of payment, health outcomes, health status, and satisfaction with 
care of Medicare beneficiaries51. To improve the accuracy and completeness of healthcare use 
and costs, survey data are matched, reconciled, and supplemented with fee-for-service Medicare 
claims creating the best of both survey and claims data worlds49.  
From 1992 to 2013, the MCBS released two data files, the “Access to Care” (AC) and the 
“Cost and Use” (CU) files, annually. While both AC and CU files include some common 
elements, AC files provide additional information on access to care, information needs, patient-
provider relationships, and satisfaction with care on “always enrolled” Medicare beneficiaries.  
CU files include detailed data on reconciled cost and use information on “ever enrolled” 
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Medicare beneficiaries 51.  Medicare claims have information on all reimbursed healthcare 
encounters of fee-for-service Medicare beneficiaries including International Classification of 
Diseases 9th Edition (ICD-9) codes, payments, procedures, and other treatments.  
For this study, we used AC and CU files and fee-for-service Medicare claims from 2006 to 
2013.  We selected these years because of the introduction of Medicare Part D program 
beginning in 2006.  We used AC files to capture information on CRN. We used CU files for 
deriving other variables. We identified asthma-COPD status by using fee-for-service inpatient, 
outpatient, physician, and home healthcare Medicare claims files.  
Study Sample  
The study sample included community-dwelling elderly (age > 65 years) Medicare 
beneficiaries who were enrolled in fee-for-service (Parts A and B) during the calendar year and 
alive throughout the calendar year.  We further restricted our study sample to those with 
available information in both AC and CU files of the MCBS and those without missing data for 
CRN measures (N = 37,571). (Appendix 7.7) 
Measures 
Dependent Variable: Any CRN (Yes/No) and Specific Forms of CRN   
 In MCBS, four questions queried CRN-related behaviors. The validity and reliability of 
using these questions for measuring CRN have been confirmed in previous studies107–109. 
Respondents were asked,  “Please tell me how often during (CURRENT YEAR) you did any of 
the following behaviors (1) decided not to fill a prescription because it cost too much, (2) 
delayed getting a prescription filled because the medicine cost too much, (3) skipped doses to 
make the medicine last longer, (4) taken smaller doses of a medicine to make the medicine last 
longer”.  The answers were recorded on a 3-point scale (often, sometimes, and never).  If 
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respondents answered “often or sometimes” to any of these questions, the respondents were 
considered to have any CRN, and those who responded never to all the questions were 
considered to have no CRN. For all specific forms of CRN, we combined “often” and 
“sometimes” to create indicator variables (Yes/No). 
Key Independent Variable: Asthma and COPD categories   
 The key independent variable was asthma-COPD status. The first step of preparing this variable 
was identification of individuals with either asthma or COPD by using the ICD-9 codes available in 
Medicare claims (Appendix 7.2). These diagnosis codes for asthma and COPD have been utilized in 
previously published research73,74.  Individuals with at least one inpatient visit or two outpatient visits (at 
least 14 days apart) for either asthma or COPD codes were considered to have diagnosed asthma or 
COPD.  Based on the presence of asthma or COPD, we created the following four categories: 1) Asthma 
and COPD (ACO); 2) Asthma without COPD; 3) No asthma with COPD; and 4) No asthma and No 
COPD. 
Other independent Variables  
We used Anderson’s health behavior model as well as published literature to guide the 
selection of other independent variables associated with CRN.  We selected Andersen behavior 
model for this study as it gives us a comprehensive list of factors associated with CRN. Per the 
framework, CRN may be affected by: 1) pre-disposing variables (Sex (Male/female); age (65-
74/75-84/ 85 years or older); race/ethnicity (White/Black/Hispanic/or other races)); 2) enabling 
factors (marital status (married/not married); education level (less than high school/high 
school/and above high school); poverty status [based on income relative to the level of federal 
poverty line (FPL)] (< 200% of FPL>= 200% of FPL)); high burden of OOP prescription cost 
([annual OOP prescription costs > annual 10% of income] (yes/no); high burden of OOP medical 
costs [annual OOP medical costs > annual 10% of income] (yes/no); and prescription drug 
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coverage (yes/no));  3) need factors (the number (1-6) of chronic conditions (cancer, diabetes, 
hypertension, heart disease, arthritis, and osteoporosis)); the number of unique medications; 
personal health practices (obesity status (yes/no); and smoking status (never-
smoker/former/current smoker).  
Statistical analyses 
 Unadjusted group differences in terms of asthma-COPD status were tested with Rao-
Scott Chi-square tests. We used separate logistic regression models to examine the unadjusted 
and adjusted associations between asthma-COPD status and CRN (i.e. any CRN and specific 
forms of CRN).  Results are presented in terms of unadjusted (UOR) and adjusted odds ratios 
(AOR) and 95% confidence intervals (CI). All analyses utilized the SURVEY procedures of 
Statistical Analysis Software (SAS®) version 9.4 to account for the complex survey design of 
MCBS.  
3.4 Results 
The study sample consisted of 37,571 person-years and included elderly (age > 65 years) 
community-dwelling, full-year fee-for-service Parts A and B Medicare beneficiaries, without 
missing data on CRN measures between 2006 and 2013. (Appendix 7.8) The overall prevalence 
of ACO, asthma-only, and COPD-only was 1.5%, 2.3%, and 8.8% respectively during the study 
period.  
There were significant differences between asthma-COPD status groups in terms of sex, 
age, race/ethnicity, marital status, education level, poverty status, prescription coverage, high 
burden of prescription cost, high burden of medical cost, the number of chronic conditions, and 
number of unique medications (Table 3.1).  For example, individuals with ACO have the highest 
rates of high burden of OOP prescription costs (9.3%) and OOP medical costs (28.3%) compared 
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to individuals with asthma-only (6.2% & 17.1%), COPD-only (9.0% & 20.9%), and no-asthma 
no-COPD (4.0% and 11.0%). The number of unique medications was the highest among 
individuals with ACO (16.21+0.34) compared to those with asthma-only (12.74+0.29), COPD-
only (12.51+0.17), and no-asthma no-COPD (7.37+0.06). 
Unadjusted and Adjusted Associations of ACO to any CRN 
The prevalence of any CRN was 9.7% among older Medicare beneficiaries. Individuals 
with ACO had the highest percentage of any CRN (16.0%) compared with individuals with 
asthma-only (14.5%), COPD-only (13.0%), and no-asthma no-COPD (9.1%) (Figure 3.1).  
Compared to individuals with no-asthma no-COPD, individuals with ACO (UOR = 1.89, 95% 
CI = [1.45, 2.45]) were more likely to report CRN (Table 3.2).  In models without adjustments 
for number of unique medications, individuals with ACO were more likely to report (AOR = 
1.50, 95% CI = [1.14, 1.96]) any CRN compared to individuals with no-asthma no-COPD (Table 
2). In the fully adjusted model for any CRN, those with ACO were as likely as those with no 
asthma and COPD to report CRN (AOR = 1.23, 95% CI = [0.92, 1.63], p = 0.15).  
Association of ACO to specific forms of CRN 
Those with ACO had the highest percentages of three specific forms of CRN including: 
failing to fill prescription (10.1%), delaying filling prescription (7.9%), and skipping medication 
doses (6.9%) (Figure 3.1).  In the unadjusted and adjusted models, without number of unique 
medications, individuals with ACO had higher odds of “failing to fill prescription”, “delaying 
filling prescriptions”, and “skipping medication doses”, compared with individuals with no-
asthma no-COPD (Table 3.3).  
In the fully adjusted model that included the number of medications as one of the 
independent variables, those with ACO (AOR = 1.43, 95% CI = [0.99, 2.07], p = 0.05), had 
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marginally higher odds of “failing to fill prescription” compared to those with no asthma and no 
COPD. In the fully adjusted models for other specific forms of CRN, we did not observe 
statistically significant differences among adults with ACO and adults with no asthma and no 
COPD.   
Comparison ACO with asthma-only and COPD-only groups 
Comparisons were also made among asthma or COPD categories (asthma only, COPD 
only).  As indicated in Table 3.2, we also used COPD-only or asthma-only as reference groups. 
In all the models, there were no statistically significant group differences among asthma only, 
COPD only, and ACO. 
3.5 Discussion 
One in six older Medicare beneficiaries with ACO reported any CRN between 2006 and 
2013. The most prevalent form of CRN was “failing to fill prescription,” which was almost twice 
as high among Medicare beneficiaries with ACO compare to those with no-asthma and no-
COPD.  
Older adults with ACO were more likely to report any CRN compared to older adults 
with no-asthma no-COPD; while not directly studied, this likely has significant later-in-life 
morbidity and mortality consequences76,98.   This is not surprising because older adults who had 
high OOP burden compared to those with neither asthma nor COPD and high OOP burden was 
significantly associated with CRN.  The high OOP burden among adults with ACO can be 
explained by the high cost of brand-name inhaler therapies and the high medication burden per 
individualized regimen to adequately manage ACO (often 2 to 3 inhaler therapies).  Although, 
we did not distinguish between asthma and COPD-related medications, we speculate that those 
with ACO need to use inhalers for the management of ACO, as these are first line therapy per the 
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most recent guidelines110. The cost of inhalers dramatically increased in 2008, after the banning 
of chlorofluorocarbon propellants111. This led to phasing out generic inhalers, leaving only 
maintenance, brand-name inhalers112. A study by Tseng et al indicated that although inhalers 
were universally covered by Medicare Part D plans, it required high cost-sharing by Medicare 
beneficiaries64. This can be seen as patients experience higher annual plan deductibles and 
elevated copay costs (inhalers are often included in higher tiers of formularies because of their 
brand status) despite Medicare covering a portion of the prescription.  For instance, using a 
single inhaler each month had projected annual OOP costs of $900 under a standard Part D plan 
in 201564.  Our study findings suggest that policy makers may need to re-evaluate coverage of 
inhalers under Part D plans.  
In our study, increased risk of any CRN among ACO individuals compared to those with 
no-asthma or no-COPD is apparent by adjusting all factors without number of unique 
medications. However, the inclusion of number of unique medications attenuated this 
association, suggesting that number of medications may be a key link between ACO and CRN. 
Notably, the mean number of unique medications is approximately 16 among individuals with 
ACO which is significantly higher compared to individuals with asthma-only (~13), COPD-only 
(~12.5), and no-asthma no-COPD (~7). Individuals with ACO have a higher number of unique 
medications due to two following reasons: (1) individuals with ACO may need to use a higher 
number of respiratory medications to adequately control respiratory symptoms. The Latin 
American Project for the Investigation of Obstructive Lung Disease (PLATINO) study found 
that 49% of individuals with ACO used respiratory medications significantly higher than 
individuals with asthma-only (38%) or COPD-only (20%)13; (2) ACO individuals may need to 
use a greater number of non-respiratory medications due to higher risk of comorbid medical 
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conditions. In our study, 43% of ACO individuals had 4-6 other chronic conditions, while this 
number was lower among individuals with asthma-only (33%), COPD-only (36%), and no-
asthma no-COPD (23%). A population survey in the US similarly found that 90% of individuals 
with ACO had at least one other co-existing condition (compared with 71% in asthma-only and 
84% in COPD-only)14.   
Taken together, all these findings suggest that reducing the number of medications may 
directly reduce the likelihood of CRN, and indirectly alleviate the high burden of OOP 
prescription cost among older adults with ACO. As documented in published literature, 
clinicians and pharmacists can play an important role in deprescribing unnecessary medications. 
For example, during annual wellness visits, now covered by Medicare,  a comprehensive review 
of medications can be performed and highlight opportunities for prescription regimen 
optimization113.  Providers can proactively participate in deprescribing by: 1) discontinuing 
unnecessary therapy, 2) discontinuing duplicate therapies, 3) combining therapies as appropriate 
(i.e. combination inhalers), and 4) replacing high-cost therapies with more affordable options.  In 
a survey of elderly Medicare beneficiaries, more than 30% of individuals reported they did not 
have the chance of talking with their provider about their medications in the last 12 months114.  
Intensive, chronic care management can be optimized through team-based care. 
 Another possible strategy to reduce number of medications is using non-pharmacological 
approaches such as lifestyle modification instead of prescribing medication. The Trial of 
Nonpharmacologic Interventions in the Elderly demonstrated that reduced sodium intake and 
weight loss could help discontinuation of antihypertensive medications in almost 40% of the 
intervention group115,116. In addition to previous strategies,  "time to benefit" (TTB) in relation to 
medication prescribing for older patients with multi-comorbidities can be utilized 117. TTB is a 
  44 
measurement of the time to significant observable benefit in randomized clinical trials of a 
medication compared with controls. This type of information is not routinely available. In the 
future, this may help guide clinicians to discontinue some medication prescriptions for older 
individuals when up-titration of a regimen was quicker than TTB. 
Strengths and Limitations 
To date, ours is the first study to examine the association between ACO and CRN among 
a nationally representative sample of fee-for-service community-dwelling Medicare 
beneficiaries. Medicare claims enabled us to identify current asthma and COPD status. Survey 
data provided the opportunity to control for a comprehensive set of covariates that are otherwise 
not available in claims data.  
This study also has some limitations. Many variables in this study including CRN are 
self-reported, which may be subject to recall bias and social desirability bias. The findings of this 
study are not generalizable to all elderly Medicare beneficiaries as Medicare HMO enrollees or 
institutionalized beneficiaries were not included in this study.  Despite the benefits of linked 
survey modules with claims, information about the age of onset, and the severity of ACO, 
asthma, COPD were not available in the dataset. Another limitation of this study is that CRN 
measures are for all types of medications and not for a specific medication group (e.g. inhalers). 
Finally, the study design is a cross-sectional study which makes it hard to establish a cause and 
effect relationship. Future cohort studies may help to evaluate the association between ACO and 
CRN.  
3.6 Conclusion 
CRN remains an issue among elderly Medicare beneficiaries. Individuals with ACO are 
vulnerable for any CRN and its specific forms. The high number of medications used among 
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ACO individuals explained the association of ACO to CRN. Interventions which target reducing 
therapy burden and cost are needed to reduce CRN and prevent downstream effects of 
medication nonadherence in patients with ACO.
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Note:  Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in 
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use 
and access to care files.  
Significant group differences in asthma-COPD status were based on Rao-Scott chi-square tests. ANOVA test was used for number of 
unique medications. 
FPL: federal poverty level; N: unweighted number; Sig: significance; Wt: weighted; †: Mean; ‡: Standard Error; ***p<.001  
Table 3.1 
Unweighted N and Weighted Percentages of Characteristics by 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) Status (Column %) 
Older (age > 65 years) Medicare Beneficiaries   









  N Wt. % N Wt. % N Wt. % N Wt. %  
ALL 576 1.5 849 2.3 3,446 8.8 32,700 87.4  
Sex         *** 
 Female  382  67.4  650  77.7  1,686  49.7  18,468  56.1  
 Male  194  32.6  199  22.3  1,760  50.3  14,232  43.9  
Age in Years    
     
*** 
 65-74  205  40.3  391  53.5  1,199  41.2  13,098  48.0  
 75-84  261  43.5  318  33.9  1,605  43.6  13,263  36.9  
 85 and above  110  16.1  140  12.6  642  15.2  6,339  15.1  
Race/Ethnicity    
     
*** 
 White  444  77.2  655  78.6  2,982  86.7  27,049  82.7  
 Black  46  8.0  84  9.3  164  4.7  2,269  6.8  
 Latino  48  7.8  59  6.5  142  3.9  1,863  5.8  
 Other race  37  7.0  51  5.7  151  4.7  1,449  4.7  
Marital Status    
     
*** 
 Married  220  39.5  401  48.1  1,658  49.3  17,228  55.2  
 Not married  355  60.5  447  51.9  1,786  50.7  15,462  44.8  
Education    
     
*** 
 Less than high school  191  31.7  174  19.1  1,131  31.8  7,649  21.3  
 High school  211  37.4  286  31.8  1,264  36.7  11,812  35.6  
 Above high school  172  30.8  387  49.2  1,040  31.5  13,112  43.1  
Poverty Status    
     
*** 
 Less than 200% FPL  357  59.8  411  45.1  2,036  57.7  15,316  44.2  
 At least 200% FPL  219  40.2  438  54.9  1,410  42.3  17,384  55.8  
Prescription Coverage         *** 
 Yes  405  70.7  582  66.8  2,250  65.2  20,143  60.9  
 No  171  29.3  267  33.2  1,196  34.8  12,557  39.1  
High Burden of OOP Prescription Cost    
     
*** 
 Yes  55  9.3  55  6.2  320  9.0  1,375  4.0  
 No  521  90.7  794  93.8  3,126  91.0  31,325  96.0  
High Burden of OOP Medical Cost    
     
*** 
 Yes  171  28.3  149  17.1  740  20.9  3,825  11.0  
 No  405  71.7  700  82.9  2,706  79.1  28,875  89.0  
Number of Other Chronic Conditions    
     
*** 
 0-1  53  9.0  93  11.0  419  13.0  7,122  23.6  
 2-3  273  47.6  471  56.4  1,754  50.7  17,539  53.4  
 4-6  250  43.3  285  32.6  1,272  36.3  8,035  23.0  
Number of Medications 
16.2
1† 
0.34‡  12.74†  0.29‡  12.51† 0.17‡  7.37 † 0.06‡ *** 
Calendar Year          
 2006  86  13.2  122  12.7  504  13.2  4,982  13.2  
 2007  72  10.6  120  13.0  493  12.6  4,636  12.3  
 2008  81  12.2  97  9.9  460  11.8  4,266  11.7  
 2009  64  11.1  93  11.0  407  11.9  3,701  11.4  
 2010  56  10.6  94  12.4  392  12.4  3,459  11.3  
 2011  82  15.5  115  14.1  404  13.2  3,980  13.4  
 2012  66  12.3  109  13.8  406  12.5  3,965  13.3  
 2013  69  14.6  99  13.3  380  12.6  3,711  13.3  
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Table 3.2 
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from  
Separate Logistic Regressions on Any Cost-related Medication Nonadherence  
Older (age > 65 years) Medicare Beneficiaries   
Medicare Current Beneficiary Survey, 2006-2013 
    Ref= No Asthma No COPD Ref= Asthma Only Ref= COPD Only 
    UOR 95% CI Sig UOR 95% CI Sig UOR 95% CI Sig 




1.89 [ 1.45 ,  2.45] *** 1.11 [ 0.78 ,  1.59]  1.30 [ 0.96 ,  1.76]  
 Asthma Only 1.69 [ 1.34 ,  2.14] *** Ref   
  1.17 [ 0.89 ,  1.53]  
 COPD only 1.45 [ 1.26 ,  1.67] *** 0.86 [ 0.65 ,  1.13] 
 Ref    
 No Asthma No COPD  Ref  
  0.59 [ 0.47 ,  0.75] *** 0.69 [ 0.60 ,  0.79] *** 
           
  AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 




1.50 [ 1.14 ,  1.96] ** 1.08 [ 0.76 ,  1.54]  1.19 [ 0.88 ,  1.61]  
 Asthma Only 1.38 [ 1.09 ,  1.75] ** Ref 
  1.10 [ 0.84 ,  1.43]  
 COPD only 1.26 [ 1.09 ,  1.45] ** 0.91 [ 0.70 ,  1.18] 
 Ref   
 No Asthma No COPD Ref 
  0.72 [ 0.57 ,  0.91] ** 0.79 [ 0.69 ,  0.92] ** 




1.23 [ 0.92 ,  1.63]  1.00 [ 0.70 ,  1.44]  1.10 [ 0.80 ,  1.50]  
 Asthma Only 1.22 [ 0.97 ,  1.54] 
 Ref    1.10 [ 0.84 ,  1.43]  
 COPD only 1.12 [ 0.96 ,  1.30] 
 0.91 [ 0.70 ,  1.19]  Ref    
 No Asthma No COPD Ref  
  0.81 [ 0.65 ,  1.02]  0.90 [ 0.77 ,  1.04]  
 
Note:  Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in 
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use 
and access to care files.  
COPD: Chronic Obstructive Pulmonary Disease; CRN: Cost-related Medication Non-Adherence; Ref: reference group; Sig: 
significance 
***p< .001; **.001 ≤ p < .01; *.01 ≤ p <.05 
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Table 3.3 
Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from  
Separate Logistic Regressions on Specific Forms of CRN  
Older (age > 65 years) Medicare Beneficiaries   
Medicare Current Beneficiary Survey, 2006-2013 
    
Unadjusted Models 
Fully Adjusted Models 
without Number of unique 
medications 
Fully Adjusted Models 
    
UOR 95% CI Sig 
AO
R 
95% CI Sig 
AO
R 
95% CI Sig 




1.54 [ 0.98 ,  2.43]  
1.21 [ 0.75 ,  1.94]  0.97 [ 0.60 ,  1.58] 
 
 Asthma Only 1.72 [ 1.16 ,  2.55] 
** 1.42 [ 0.95 ,  2.10]  1.24 [ 0.83 ,  1.84] 
 
 COPD only 1.49 [ 1.23 ,  1.82] 
*** 1.25 [ 1.02 ,  1.52] * 1.10 [ 0.89 ,  1.37] 
 
 No asthma No COPD          




2.16 [ 1.41 ,  3.31] *** 
1.58 [ 1.00 ,  2.50] * 1.36 [ 0.87 ,  2.11] 
 
 Asthma Only 1.62 [ 1.09 ,  2.40] 
* 1.28 [ 0.87 ,  1.87]  1.16 [ 0.79 ,  1.70] 
 
 COPD only 1.59 [ 1.32 ,  1.91] 
*** 1.31 [ 1.09 ,  1.58] ** 1.20 [ 1.00 ,  1.46] 
 
 
No asthma and No 
COPD 
   
     
 




2.25 [ 1.59 ,  3.17] *** 
1.75 [ 1.24 ,  2.47] ** 1.43 [ 0.99 ,  2.07]  
 Asthma Only 1.61 [ 1.20 ,  2.15] 
** 1.30 [ 0.97 ,  1.73]  1.15 [ 0.87 ,  1.52]  
 COPD only 1.65 [ 1.42 ,  1.92] 
*** 1.41 [ 1.20 ,  1.66] *** 1.25 [ 1.05 ,  1.49] * 
 No asthma No COPD          




2.07 [ 1.47 ,  2.93] *** 
1.48 [ 1.02 ,  2.14] * 1.26 [ 0.87 ,  1.81]  
 Asthma Only 1.79 [ 1.30 ,  2.46] 
*** 1.37 [ 0.99 ,  1.90]  1.24 [ 0.89 ,  1.71]  
 COPD only 1.69 [ 1.37 ,  2.09] 
*** 1.41 [ 1.14 ,  1.74] ** 1.28 [ 1.02 ,  1.60] * 
 No Asthma and COPD          
Note:  Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in 
fee-for-service Part A and Part B during the calendar year and alive during the calendar year, and had information in both cost and use 
and access to care files.  
CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; CRN: Cost-related Medication Non-Adherence; Sig: 
significance 







Prevalence of any CRN and Specific Types of CRN 
By Asthma-COPD Status (i.e., Asthma-COPD Overlap, Asthma-Only, COPD-Only, Neither Asthma nor COPD) 
Older (age > 65 years) Medicare Beneficiaries   
Medicare Current Beneficiary Survey, 2006-2013 
 
 
Note:  Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in fee-for-service Part A and 

























Any CRN CRN by Using Smaller Doses CRN by Skipping Some Doses CRN by Failing to Get
Prescription
CRN  by Delaying to Get
Prescription
Total Asthma-COPD Overlap Asthma Only COPD Only No-Asthma No-COPD
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CHAPTER 4  
4 Impact of Initial Maintenance Therapy Type on Medication Adherence Trajectories 
among Older Adults with Asthma and COPD Overlap 
4.1 Abstract 
Objective: To examine the impact of initial maintenance therapy (IMT) type (inhaled 
corticosteroids (ICS) vs. fixed dose combinations of ICS and long acting beta agonists 
(ICS/LABA)) on trajectories of adherence among Asthma and Chronic Obstructive Pulmonary 
Disease overlap (ACO) among older adults (> 65 years). 
Methods: This study used a retrospective cohort of older adults with ACO using longitudinal 
data from a 10% sample of Optum’s Deidentified Clinformatics ® Data Mart. We adopted 
group-based trajectory modeling to identify medication adherence trajectories over 12 months. 
Multinomial logistic regressions were used to evaluate the unadjusted and adjusted association of 
IMT medication and adherence trajectory categories. All analyses accounted for treatment option 
selection bias with inverse probability treatment weighting. 
Results: Of 1,555 individuals, 73% of the sample used ICS/LABA for IMT. Four medication 
adherence trajectories were observed regardless of regimen: 1) persistent high adherence 
(12.0%); 2) progression to high adherence (20.8%); 3) progression to low adherence (10.5%) and 
4) persistent low adherence (56.7%). Those who were initiated on ICS/LABA were less likely to 
have “persistent low adherence” (Unadjusted Odds Ratio = 0.44, 95% Confidence Interval (CI)= 
[0.29, 0.67]) as compared to those with ICS monotherapy when “persistent high adherence” was 
used as the reference group. The relationship remained significant in adjusted regressions 
(Adjusted Odds Ratio = 0.38, 95% CI = [0.24, 0.59]).  
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Conclusions: Real-world evidence suggests that using ICS/LABA for IMT may decrease the 
likelihood of “persistent” low adherence over time among older adults with ACO compared to 
ICS monotherapy.  
4.2 Introduction 
Many adults have co-existing asthma and Chronic Obstructive Pulmonary Disease (COPD) 
known as “Asthma-COPD overlap” (ACO)9. Treatment for ACO requires treating both the 
underlying asthma and COPD by using maintenance therapy with inhaled medications. The joint 
guidelines of Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) recommend inhaled corticosteroids (ICS) with or without a long-acting 
beta-agonist (LABA) for initial maintenance therapy (IMT) of individuals with ACO7,3.  
Compared to ICS monotherapy, use of ICS/LABA for IMT of ACO has some advantages. 
First, ICS/LABA can reduce both the inflammatory nature of asthma and the obstructive nature 
of COPD 19. Second, prior studies indicate using ICS/LABA may improve medication adherence 
compared to ICS. Although the association of using ICS/LABA and adherence to IMT has not 
been directly studied among patients with ACO, these findings have been noted among patients 
with asthma48,118–121. One possible reason is that the use of LABA in fixed-dose combination 
with ICS has demonstrated benefit in reducing symptoms and exacerbations quickly compared to 
ICS monotherapy which may increase the medication value to the patient122,123. Finally, one 
observational study reported that ICS/LABA reduced the risk of myocardial infarction, 
hospitalization, and death among patients with ACO, as compared to ICS monotherapy47.   
To date, no study has evaluated adherence to IMT or the effect of IMT type on medication 
adherence among older adults with ACO. However, this is a crucial topic to better understand 
because older adults are the most vulnerable group of individuals to experience poor adherence 
 52 
and subsequent negative outcomes. Older adults (age > 70 years) often have higher prevalence of 
poor medication adherence, compared to younger adults (age < 50 years), due to regimen 
complexity, polypharmacy, prescription costs, and multiple comorbidities 124,125. For example, 
prior studies have suggested that 70% of COPD patients 30 and nearly 50% of adults with 
asthma27 have poor adherence to IMT, suggesting that such patterns may also be present in older 
adults with ACO. Poor medication adherence can amplify the negative health effects of older 
adults with ACO.  Among patients with asthma or COPD, poor adherence to maintenance 
therapy is associated with increased risk of adverse events such as hospitalization, disease 
burden, and mortality. 126–128 Therefore, older individuals with ACO may also experience these 
negative consequences, perhaps to an even greater degree.   
It is important to analyze medication adherence over time because static adherence metrics 
(e.g. proportion of days covered (PDC) or medication possession ratio (MPR)) average 
adherence over time and ignore “within” individuals’ differences in adherence over time.129 For 
example, an individual who uses medications for the first six months and discontinues for the 
following six months will have the same PDC as an individual who uses the prescription every 
other month. As medication adherence is known to vary over time among adults with chronic 
lung diseases31, examination of adherence trajectories over time is important. Such information 
can precisely locate the time point at which adherence changes. Furthermore, adherence 
trajectories can guide development of customized intervention efforts at the right time130.  
Therefore, the current study used group-based trajectory modeling (GBTM) of adherence 
to IMT over time and analyzed the association of IMT type to trajectory membership among 
older adults using claims data from Optum Clinformatics ® DataMart. Although, GBTM method 
has been previously used for studying patterns of medication adherence to IMT among patients 
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with asthma25, this study is the first application of the GBTM approach for examining 
individuals with ACO. 
4.3 Methods 
Data Source 
This study used health insurance claims from a 10% sample of Optum Clinformatics ® 
DataMart from 1/1/2007 through 6/30/2017. This database contains information on prescription 
claims [e.g. NDC codes, generic drug names, prescription fill dates, days supply, and costs of 
medications], inpatient and outpatient medical claims [e.g. International Classification of 
Diseases (ICD) 9th and 10th revision diagnoses, date of service, and costs of services], and 
eligibility information [e.g. sex, date of birth, plan type, and insurance type]. 
Study Design  
 We used a longitudinal retrospective cohort design with a 24-month observation period 
(12-month baseline and 12-month follow-up periods). We anchored the baseline period and the 
follow-up period to the index date (i.e. first observed ICS or ICS/LABA fill date between 
10/1/2008 to 9/30/2016).  Baseline consisted of 12 months before the index date. The baseline 
period was used to identify ACO and other characteristics. In the 12-months follow up period, 
we measured medication adherence every month. Thus, each person had 12 observations (T1 to 
T12).  
Study Cohort: Older Adults with ACO  
Only individuals with ACO diagnosis were included in this study. The first step involved 
the identification of patients with either asthma or COPD during the baseline period. We 
identified asthma or COPD by using the International Classification of Diseases, Clinical 
Modification (ICD) 9 or ICD10 codes (Appendix 7.2). These diagnosis codes were derived from 
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published research73,74. Individuals were required to have at least one inpatient visit or two 
outpatient visits (at least 14 days apart) with either asthma or COPD codes. Individuals with both 
asthma and COPD diagnoses during the baseline were identified as indivduals with ACO.  
The study cohort included only older (age > 65 years) Medicare advantage beneficiaries 
who initiated maintenance therapy with ICS monotherapy or ICS/LABA from 10/1/2008 to 
9/30/2016.  These patients were required to have continuous enrollment in both the baseline and 
follow-up periods. We excluded individuals who used any other maintenance therapy (i.e. ICS, 
LABA, long acting muscarinic antagonist (LAMA), and their combination forms) during the 12-
month pre-index period (Appendix 7.9).  
Measures 
Dependent Variables: Medication Adherence and Medication Adherence Trajectory Categories 
derived from GBTM  
We measured adherence to ICS or ICS/LABA for every 30-days during the follow-up 
period. We created binary variables (yes/no) for each month based on the days supply for each 
month after the index date25.  These 12 dichotomized monthly indicators were used in a GBTM. 
As described below, the GBTM model yielded four medication adherence patterns: (1) persistent 
high adherence; (2) progression to high adherence; (3) progression to low adherence; and (4) 
persistent low adherence.  These categories were used as the dependent variable to analyze the 
association of IMT type to medication adherence.   
Key Independent Variable: Type of IMT (ICS and ICS/LABA) 
Two usual treatment options for IMT were ICS monotherapy and fixed-dose combination 
of ICS/LABA. National drug codes were used to identify these medications. To ensure that 
individuals used ICS or ICS/LABA as IMT, we defined a look-back period of 365 days and only 
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individuals who did not have any ICS, ICS/LABA, LABA, or LAMA use were considered as 
initiating maintenance therapy.  
Other Independent Variables 
Selection of covariates was guided by the Anderson Health behavior model50. Per the 
framework, adherence to IMT may be affected by: (1) pre-disposing variables (sex 
[male/female], age); (2) enabling factors (insurance plan [health maintenance organization 
(HMO)/Non-HMO], annual out-of-pocket  prescription costs);  (3) need factors (dementia 
[yes/no], depression [yes/no], anxiety [yes/no], diabetes [yes/no], heart diseases (the presence of 
at least one of the following: chronic heart failure, coronary artery disease, or arrhythmia) 
[yes/no], hypertension [yes/no],  the number of other chronic conditions (cancer, arthritis, 
hyperlipidemia, hepatitis, HIV, osteoporosis, chronic kidney disease, stroke), the number of short 
acting beta agonists (SABA), the number of courses of oral corticosteroids or antibiotics, 
polypharmacy [concomitant use of five or more classes of medications within a 90 day period 
before the index date]); (4) personal health practices (obesity diagnosis [yes/no] and tobacco use 
diagnosis [yes/no]; (5) external factors (region [Northeast/Midwest/ South/West]). 
Statistical Analyses 
Accounting for Selection Bias of Treatment: 
We observed significant differences in baseline characteristics by IMT type.  
Specifically, individuals using ICS/LABA were more likely to be male, enrolled in non-HMO 
plans, to be prescribed a SABA, more likely to live in the Southern region of the US, more likely 
to have clinically recorded tobacco use, and less likely to have diagnosed anxiety, as compared 
to ICS monotherapy. To control for this observed selection bias, we derived inverse probability 
of treatment weights (IPTW). IPTWs were estimated from a logistic regression in which IMT 
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type (ICS vs ICS/LABA) was the dependent variable. The covariates included sex, age, being 
enrolled in an HMO plan, out-of-pocket prescription costs, presence of diabetes, anxiety, 
depression or heart diseases, number of SABA, tobacco use diagnosis, the number of courses of 
antibiotics, and region of residency. IPTWs were then used in the GBTM of medication 
adherence. Once the medication adherence patterns were identified, we compared the unadjusted 
and adjusted associations of IMT type to the trajectory groups using the IPTW-adjusted 
multinomial logistic regressions.   
Identification of Medication Adherence Trajectory Groups: 
We identified clusters of patients with similar adherence patterns using the GBTM 
method. GBTM uses the maximum likelihood estimation to identify changes in medication 
adherence patterns over time. 131,132 GBTM uses the data to empirically group individuals. Under 
this method, patterns of adherence are identified based on linear and non-linear specifications 
and the probabilities of each individual belonging to these trajectories are calculated. Individuals 
are assigned to the group for which they have the highest probability. We used different 
specifications to identify these groups by using either cubic, quadratic, or quartic terms133,134.  
Evaluating Medication Adherence by Using Generalized Estimating equations: 
In addition to GBTM, we also used unadjusted and adjusted generalized estimating 
equations (GEE) to evaluate the association of IMT type to medication adherence over time.  We 
used population-averaged GEE for repeated measures. Results from the GEE analyses are 
summarized in Appendix 7.10. All data management and analyses were conducted with SAS 9.4 
(SAS Institute Inc., Cary, NC) and Stata 14 (Stata Corp LLC, College Station, TX) was used for 




Sample Characteristics Baseline Characteristics 
In our study cohort of older adults with ACO and initiated on ICS or ICS/SABA as IMT 
(N = 1,554), the majority were female (66.6%); mean age was 75.2 + 6.1 years. The majority of 
individuals were enrolled in an HMO plan (64.9%). The baseline characteristics of our study 
cohort is provided in Appendix 7.11.  An overwhelming majority (73.2%) used ICS/LABA and 
26.8% used ICS for IMT.  
IPTW-adjusted Baseline Characteristics by IMT Type   
The unweighted numbers and IPTW-adjusted weighted percentages baseline 
characteristics by IMT type are displayed in Table 1.  As can be seen in Table 1, there were no 
statistically significant differences in baseline characteristics between the two groups after IPTW 
adjustments.  
Identification of Medication Adherence Trajectories with GBTM 
We initially specified eight groups with quadratic and higher-order polynomial 
specifications.  After a preliminary examination of the results, we finalized trajectories to four 
groups based on the following criteria:  1) the Bayesian information criterion (BIC); 2) 
significant p-values (<.05) for the highest-order polynomial parameter; 3) at least 5% of the 
population assigned to each trajectory group; 4)  no polynomial overfitting; 5) narrow confidence 
intervals; and 6) clinically meaningful grouping131,135–137. The final trajectory model passed all 
Nagin's diagnostic criteria of the “average of posterior probabilities (PP) >0.7” and the “odds of 
correct classification (OCC) >0.5” for all groups 131,136.  
As shown in Figure 1, we identified four different adherence trajectories. These 
trajectories can be described as: (1) persistent low adherence (56.7%); (2) persistent high 
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adherence (12.0%), 3) progression to low adherence (10.5%); and (4) progression to high 
adherence (20.8%).  
Unadjusted and Adjusted Associations of IMT type to Adherence Trajectory Groups 
The four adherence trajectories were significantly different in terms of IMT type (Table 
2) with a higher percentage of individuals who used ICS/LABA having “persistent high 
adherence”, compared to those prescribed ICS monotherapy (82.9% vs. 68.1). Unadjusted odds 
ratios (UOR), adjusted odds ratios (AOR), and 95% Confidence intervals (CI) from the 
multinomial logistic regressions on medication adherence categories are summarized in Table 3. 
In the unadjusted multinomial logistic regression models, those who were initiated on 
ICS/LABA were 56% less likely to have “persistent low adherence” (UOR = 0.44, 95% CI [0.29, 
0.67]), compared to those with ICS monotherapy when “persistent high adherence” was used as 
the reference group for the dependent variable. The relationship remained significant in adjusted 
regressions that controlled for only predisposing factors (AOR = 0.44, 95% CI = [0.29, 0.66]) 
and remained significant in all subsequent models. In the fully adjusted model, those with 
ICS/LABA as IMT were less likely to have “persistent low adherence” (AOR= 0.37, 95% CI = 
[0.24, 0.59]). 
4.5 Discussion 
This study is the first study to report longitudinal patterns of adherence to IMT among 
older adults with ACO seeking care in real-world practices and who were initiated on ICS or 
ICS/LABA for maintenance therapy by using a GBTM approach. In our study cohort of older 
adults with ACO, ICS/LABA use was very common, with three in four older adults using 
combination therapy. In a study conducted on adults (>18 years) using 2008 and 2011 Truven 
Health Analytics MarketScan Commercial and Medicare Supplemental databases approximately 
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75% of adults with ACO and on maintenance therapy were prescribed ICS/LABA 74. The 
differences in the prevalence rate of ICS/LABA can be due to differences in study population, 
time period, and insurance coverage.  
We identified four distinct patterns of medication adherence: 1) persistent low adherence; 
2) persistent high adherence; 3) progression to low adherence and 4) progression to high 
adherence. Overall, the majority of older adults (57%) had persistent poor adherence and only 
11% had “persistent high adherence.” As there are no published studies on medication adherence 
trajectories over time among older adults with ACO, we compared our results to studies that 
focused on adults with asthma or COPD. A recent study conducted in Australia reported that the 
“persistent low adherence” trajectory to IMT was observed among 58% of individuals between 
12 and 45 years old. Studies that use PDC for measuring medication adherence also reported the 
high prevalence of medication non-adherence (<80% PDC) among patients with asthma or 
COPD. For example, a systematic review of 39 clinical trials reported that only 47% to 57% of 
individuals with asthma were adherent to maintenance therapy27. Moreover, in a retrospective 
cohort study on Medicare beneficiaries with COPD, the average monthly adherence to IMT was 
plateaued at 35% by the seventh month31. Our study’s findings demonstrating that the majority 
of older adults with ACO had persistent low adherence is concerning. This finding suggests that 
there is a significant room for improvement in adherence to achieve better disease management, 
improved patient safety, and reduced exposure to unnecessary treatment intensification.  
The results of this study confirmed that the adherence to IMT varies over time. For 
example, one third of patients changed their adherence behavior after six months of starting IMT. 
This may indicate a heightened surveillance of adults who were initiated on IMT, and there may 
be a limited “window of opportunity” to deliver evidence-based interventions that improve 
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adherence. Although there are many types of interventions to improve medication adherence 
among individuals with asthma or COPD, motivational interviewing138, coaching and patient 
education 139, shared decision-making140, and simplification of regimen141 have been proven to 
improve adherence. Our study findings suggest that these interventions may need to be delivered 
at the right time to improve medication adherence.   
Our study findings also suggest that the type of therapy (type of IMT) may be an 
important modifiable factor for reducing the risk of consistent low-adherence.  In our study, 
older adults who were initiated on ICS/LABA were less likely to have “persistent low 
adherence”. Previous studies among patients with asthma also support this finding. A clinical 
trial conducted by Perrin et al. reported that adherence to ICS/LABA was marginally higher, as 
compared to ICS monotherapy142. Similarly, four observational studies among patient with 
asthma concluded that that use of ICS/LABA is likely to improve adherence to IMT or 
maintenance therapy compared with ICS 48,118–121. As stated in the introduction ICS/LABA 
confers many advantages. Although many patients perceive that inhalers are effective in 
relieving symptoms, this perceived efficacy of ICS/LABA may be higher. This higher perceived 
efficacy can be due to a faster improvement of symptoms by using ICS/LABA. A previous 
clinical trial among patients with asthma has reported that ICS/LABA resulted in a faster 
improvement in asthma symptoms compared to ICS monotherapy for IMT143. While simplifying 
a medication regimen is optimal for improved adherence, prescribers do not need to order two 
inhalers to achieve dual therapy; ICS/LABA are available in combination as one inhaler.  Future 
randomized clinical trials are needed to investigate the differences in improvement of symptoms 
between ICS/LABA and ICS for IMT of ACO. Our study findings also suggest that therapy-
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related factor (type of IMT) may be an important modifiable factor in reducing the risk of 
consistent low-adherence. 
4.6 Limitations 
This study has some limitations. One limitation is the use of medication fills data for 
assessing adherence. In fact, adherence based on medication fills data assumes that filled 
medications are taken and used properly by patients. This assumption can result in 
overestimating adherence. As this study used retrospective cohort design using claims data, it has 
the inherent limitations of the observational study (under coding of diagnosis, lack of clinical 
markers of disease severity, and lack of information on behavioral variables). Other factors that 
may impact adherence to IMT (e.g. patient-physician communication, severity of symptoms, fear 
of side effects, and family support) were not adjusted, and this may change the impact of IMT 
type on adherence behavior. 
4.7 Conclusion 
 Among older adults with ACO seeking care in real-world settings, we identified potential 
concern with high rates of non-adherence based on fill rates.  Our study findings suggest that 
using ICS/LABA for IMT may reduce the risk of “persistent low adherence” over time among 
older adults with ACO. Future studies need to target older with consistently low adherence to 
maintenance therapy to explore drug-related and non-drug-related factors that are barriers or 




Note: Based on 1,556  older adults aged 65 years or older with ACO diagnosis, initiated on maintenance therapy  (either 
inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting beta agonist) and 
continuously enrolled during the observation period.  
Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization;  SABA: Short-Acting 
Beta Agonist; SD: Standard deviation; Sig: Significance; Wt: Weight; #: Number    
Table 4.1 
Characteristics of Older Adults with Asthma-COPD Overlap 
by Initial Maintenance Therapy Options 
Inverse Probability Treatment Weighting 
Optum Clinformatics 10% Sample, 2007-2017 
  ICS/LABA ICS  
  N/ Mean Wt % N Wt % Sig 
ALL  1137 73.2 417 26.8  
Sex        
Female 757 66.6 276 66.4   
Male 380 33.4 140 33.6  
Age (Mean, SD) 75.01 6.06 75.75 6.27  
Insurance Plan       
HMO 739 64.9 270 64.9   
Non- HMO 399 35.1 146 35.1  
Out-of-pocket Payments for 
Prescription Drugs (Mean, SD) 533.22 739.23 552.41 750.56 
 
Depression      
 Yes 145 12.8 52 12.4  
 No 992 87.2 365 87.6  
Anxiety      
 Yes 120 10.5 44 10.5  
 No 1018 89.5 373 89.5  
Diabetes      
 Yes 410 36.0 165 39.6  
 No 727 64.0 252 60.4  
Hypertension      
 Yes 802 70.5 304 72.9  
 No 335 29.5 113 27.1  
Heart Diseases       
 Yes 481 42.3 171 41.1  
 No 656 57.7 245 58.9  
# Other Chronic Conditions       
 0 218 19.2 70 16.7  
 1-2 708 62.2 268 64.4  
 3-4  211 18.6 79 18.9  
# SABA (Mean, SD) 1.75 2.77 1.78 2.73  
Polypharmacy       
 Yes 794 69.8 303 72.7  
 No 343 30.2 114 27.3  
Obesity Diagnosis      
 Yes 198 17.4 66 15.9  
 No 939 82.6 350 84.1  
Tobacco Use Diagnosis      
 Yes 143 12.6 50 11.9  
 No 994 87.4 367 88.1  
Region      
 Northeast 125 11.0 46 10.9  
 Midwest 200 17.6 74 17.7  
 South 442 38.9 161 38.8  
 West 369 32.5 136 32.6  
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Note: Based on 1,556 older adults aged 65 years or older with Asthma Chronic Obstructive Pulmonary Disease Overlap, initiated 
on maintenance therapy (either inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting 
beta agonist) and continuously enrolled during the observation period. 
Table 4.2 
Characteristics of Older Adults with Asthma-COPD Overlap 
By Medication Adherence Trajectories   
Initiated on Maintenance Therapy 
Optum Clinformatics 10% Sample, 2007-2017 









  N Wt % N Wt % N Wt % N Wt %  
ALL 891 57.3 322 20.7 166 10.7 177 11.4  
IMT Type          *** 
 ICS/LABA 607 68.1 257 79.8 128 77.1 145 82.9  
 ICS 284 31.9 65 20.2 38 22.9 30 17.1  
Sex           
Female 596 66.9 207 64.3 115 69.3 117 66.9   
Male 295 33.1 115 35.7 51 30.7 58 33.1  
Age (Mean, SD) 75.1 6.1 75.1 6.0  75.2 6.2 75.9 6.2 *** 
Insurance Plan           
HMO 579 65.0 211 65.5 112 67.5 107 61.1   
Non- HMO 312 35.0 111 34.5 54 32.5 68 38.9  
OOP Prescription Costs 
in hundreds (Mean (SD)  
5.3 7.0 5.9 9.1 6.1 7.7 3.9 4.8 * 
Depression          
 Yes 126 14.1 34 10.6 18 10.8 23 13.1  
 No 765 85.9 288 89.4 148 89.2 152 86.9  
Diabetes         ** 
 Yes 354 39.7 116 36.0 47 28.3 52 29.7  
 No 537 60.3 206 64.0 119 71.7 123 70.3  
Heart Diseases         + 
 Yes 398 44.7 130 40.4 58 34.9 66 37.7  
 No 493 55.3 192 59.6 108 65.1 109 62.3  
# Other Chronic 
Conditions  
         
 0 163 18.3 58 18.0 30 18.1 35 20.0  
 1-2 556 62.4 211 65.5 107 64.5 104 59.4  
 3 and more 172 19.3 53 16.4 29 17.5 36 20.5  
# SABA           *** 
 0 342 38.4 115 35.7 64 38.6 51 29.1  
 1-3 455 51.1 151 46.9 72 43.4 81 46.3  
 4-6 62 7.0 34 10.6 17 10.2 25 14.3  
 > 7 32 3.6 22 6.8 13 7.8 18 10.3  
> 2 Courses of Antibiotics          * 
 Yes 469 52.6 148 46.0 78 47.0 72 41.1  
 No 422 47.4 174 54.0 88 53.0 103 58.9  
Polypharmacy           
 Yes 628 70.5 225 69.9 120 72.3 124 70.9  
 No 263 29.5 97 30.1 46 27.7 51 29.1  
Obesity Diagnosis          
 Yes 158 17.7 59 18.3 23 13.9 20 11.4  
 No 733 82.3 263 81.7 143 86.1 155 88.6  
Region          
 Northeast 100 11.2 32 9.9 19 11.4 21 12.0  
 Midwest 133 14.9 71 22.0 31 18.7 38 21.7  
 South 363 40.7 117 36.3 67 40.4 58 33.1  
 West 295 33.1 102 31.7 49 29.5 58 33.1  
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Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization; ICS: Inhaled Corticosteroid; 
ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist; IMT: Initial Maintenance Therapy; N: 
Number; OOP: Out of Pocket; SABA: Short-Acting Beta Agonist; SD: Standard deviation; Sig: Significance; Wt: Weight; #: 






Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from  
Multinomial Logistic Regressions on Medication Adherence Trajectory Groups  
with Persistent High Adherence as Reference Group 
Inverse Probability Treatment Weighting  
among Older Medicare Beneficiaries with ACO and Initiated on Maintenance Therapy 
Optum Clinformatics 10% Sample, 2007-2017 
  Persistent Low Adherence Progression to Low 
Adherence 
Progression to High 
Adherence 
  UOR 95% CI Sig UOR 95% CI Sig UOR 95% CI Sig 
Model 1: Unadjusted  
IMT Type  (Ref: ICS)          
       ICS/LABA 0.44 [ 0.29 ,  0.67] *** 0.79 [ 0.49,  1.28]  0.69 [ 0.40 ,  1.18]  
  AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Model 2: Adjusted by Predisposing Factors  
IMT Type  (Ref: ICS)          
       ICS/LABA 0.44 [ 0.29 ,  0.66] *** 0.79 [ 0.49,  1.27]  0.69 [ 0.40 ,  1.18]  
 
Model 3: Adjusted by Predisposing and Enabling Factors  
IMT Type  (Ref: ICS)          
       ICS/LABA 0.44 [ 0.29 ,  0.67] *** 0.79 [ 0.49,  1.27]  0.69 [ 0.40 ,  1.18]  
 
Model 4: Adjusted by Predisposing, Enabling, Personal Health Practice and External Factors  
IMT Type Status (Ref: ICS)          
       ICS/LABA 0.43 [ 0.28 ,  0.66] *** 0.78 [ 0.48,  1.26]  0.67 [ 0.39 ,  1.16]  
 
Model 5: Adjusted by Predisposing, Enabling, Personal Health Practice, External , and Need Factors  
IMT Type (Ref: ICS)          




Note: Based on 1,556 older adults aged 65 years or older with Asthma Chronic Obstructive Pulmonary Disease overlap, initiated on 
maintenance therapy (either inhaled corticosteroid only or fixed dose combination of inhaled corticosteroids and-long-acting beta 
agonist) and continuously enrolled during the observation period. 
 
Pre-disposing factors were sex, and age.  Enabling factors consisted of insurance plan type, annual out-of-pocket payments for 
prescription drugs. Personal health practices were: Obesity diagnosis and tobacco use recorded in claims. External environmental 
factors included region of residency.  Need factors were: dementia, depression, anxiety, diabetes, heart diseases, hypertension, the 
number of other chronic conditions, the number of SABA, the number of courses of oral corticosteroids, the number of courses of 
antibiotics, and polypharmacy. 
 
Abbreviations: ACO: Asthma Chronic Obstructive Pulmonary Disease Overlap; ICS: Inhaled Corticosteroid; ICS/LABA: Fixed dose 







Trajectories of Adherence to Initial Maintenance Therapy  
Among Older (> 65 years old) Adults with Asthma-COPD Overlap 






5 Summary and Conclusion 
5.1 Summary of Findings and Discussion 
Prevalence of ACO 
 In our study, the overall prevalence of ACO was 1.5% among community dwelling 
Medicare beneficiaries. Although no study has reported the specific prevalence of ACO among 
community dwelling Medicare beneficiaries, this estimate is less than 3.8% which was 
previously reported by Kumbhare et al for (65-85 years old) older adults in the United States14. 
Possible explanations of this difference are methods of identification and time period. While this 
study used fee-for-service Medicare claims for identification of ACO during a calendar year 
Kumbhare et. Al. used “ever diagnosed” using self-reports. Thus, we may have captured only 
older adults who had received healthcare services for asthma and COPD.  
Excess Economic Burden of ACO in Terms of Total Health Care Expenditures and Third-
Party Payers’ Expenditures  
 In terms of projected total healthcare expenditures, nearly two billion dollars (2013USD) 
were spent on healthcare (weighted number of ACO adults in 2013= 42,984 multiplied by the 
average per-capita cost $45,532) of older community-dwelling adults with ACO. In terms of the 
excess economic burden (i.e. total health care expenditures and third-party payers’ expenditures) 
individuals with ACO had almost four, two, and 1.5 times higher expenditures compared to 
individuals with NANC, asthma only, and COPD only. Even after controlling for multiple 
determinants of expenditures, the presence of ACO was associated with significantly higher 
expenditures in comparison with individuals with NANC, asthma only, and COPD only – 
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consistent with published studies that compared per-capita expenditures of individuals with ACO 
to those with asthma only17 or those with COPD only18.  
 The excess expenditures associated with ACO is not surprising because studies have 
documented increasing expenditures with an increasing number of chronic conditions80. 
Furthermore, our finding that ACO patients had higher economic burden compared those with 
asthma only or COPD only suggest that ACO adults may have higher rates healthcare utilization 
including hospitalization and emergency department/urgent care visits, which contribute to the 
higher expenditures. In a cohort of 17,088 COPD patients in Taiwan, ACO patients experienced 
almost twice as many acute respiratory events (e.g. acute respiratory failure, pneumonia, and 
acute exacerbation) than did the rest of the COPD cohort12.   
Excess Economic Burden of ACO for Patients and Their Families: Out-of-Pocket 
Healthcare Expenditures  
 In this study, those with ACO had higher odds of high OOP spending burden compared 
to all other groups in both unadjusted and adjusted models. This high burden could be due to 
cost-sharing of Medicare-covered services, including prescription drugs and payments for non-
covered services by Medicare. OOP burden may be particularly high among individuals with 
ACO because of high cost-sharing of inhaler medications. Based on data from nationwide Part D 
plans, it has been estimated that mean OOP expenditures were $30–$105 per inhaler in 201564. 
This means that a typical older Medicare beneficiary with ACO who is prescribed 2-3 inhalers 
per month has annual OOP expenditures of at least $1,622–$2,81l for his/her inhalers64. 
 Individuals with ACO may have greater need for some of the services not covered by 
Medicare (example: dental, hearing, and vision) compared to NANC as they are higher risk of 
these conditions. For example, individuals with ACO have significantly higher odds (AOR = 
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1.82, 95% CI = [1.59, 2.08], P<0.001) of removing all teeth compared to NANC81, suggesting 
greater spending on oral healthcare by patients. It has also been reported that COPD patients are 
vulnerable to low-value care82, which may increase OOP spending of families and patients 
through cost-sharing. Medicare reform proposals that focus on value-based healthcare that 
balance the value of health services to the OOP spending burden of patients may reduce the 
excess economic burden of patients. 
Contribution of Differences in Patient Characteristics to the Excess Economic Burden of 
ACO 
 The current study used linear and non-linear decomposition analyses to examine the 
drivers of the excess economic burden of chronic respiratory conditions, one of the top four 
conditions of public health concern designated by the World Health Organization (WHO)83. The 
other three conditions are cardiovascular disease, diabetes, and cancer. It has to be noted that 
older adults with chronic respiratory conditions also have higher rates of CVD, diabetes, and 
cancer. A population survey among (>18 years) adults in the US also found that the adjusted 
odds of six chronic conditions (e.g. cardiovascular diseases, diabetes, and depression) is higher 
in ACO compared to asthma only and COPD only 14. In our study, 91% of ACO patients had 
more than two other chronic conditions which was higher than asthma only (89%), COPD only 
(87%) and NANC (76%) groups. Our decomposition analysis suggested that patient-level 
characteristics such as higher number of co-existing chronic conditions and related 
characteristics (i.e., higher number of unique medications, and higher levels of fragmented care) 
were the leading drivers of the excess economic burden among ACO patients. For example, 
receiving care from several different providers often results in gaps in communication between 
providers which can lead to suboptimal care and polypharmacy75,84. Prior studies suggest that 
 
70 
more fragmented care is associated with more diagnostic tests, more low-value care, and lower 
patient satisfaction85–87. Previous studies further suggest the associations of fragmented care and 
higher number of emergency department (ED) visits, higher hospitalizations, and higher 
expenditures77,88. 
Cost-Related Medication Non-Adherence and ACO 
  One in six older Medicare beneficiaries with ACO reported any CRN between 2006 and 
2013. The most prevalent form of CRN was “failing to fill prescription,” which was almost twice 
as high among Medicare beneficiaries with ACO compare to those with no-asthma and no-
COPD. Older adults with ACO were more likely to report any CRN compared to older adults 
with no-asthma no-COPD; while not directly studied, this likely has significant later-in-life 
morbidity and mortality consequences76,98. This is not surprising because older adults with ACO 
compared to those with neither asthma nor COPD had higher OOP burden, and high OOP burden 
was significantly associated with CRN. The high OOP burden among adults with ACO can be 
explained by the high cost of brand-name inhaler therapies and the high medication burden per 
individualized regimen to adequately manage ACO (often two to three inhaler therapies).   
Role of Number of Medication in High Risk of CRN among Patients with ACO 
 In our study, increased risk of any CRN among ACO individuals compared to those with 
no-asthma no-COPD is apparent by adjusting all factors without number of unique medications. 
However, the inclusion of number of unique medications attenuated this association, suggesting 
that number of medications may be a key link between ACO and CRN. Notably, the mean 
number of unique medications is approximately 16 among individuals with ACO which is 
significantly higher compared to individuals with asthma-only (~13), COPD-only (~12.5) and 
no-asthma no-COPD (~7). Individuals with ACO have a higher number of unique medications 
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due to two following reasons: (1) individuals with ACO may need to use a higher number of 
respiratory medications to adequately control respiratory symptoms. The Latin American Project 
for the Investigation of Obstructive Lung Disease (PLATINO) study found that 49% of 
individuals with ACO used respiratory medications significantly higher than individuals with 
asthma-only (38%) or COPD-only (20%)13; (2) ACO individuals may need to use a greater 
number of non-respiratory medications due to higher risk of comorbid medical conditions. In our 
study, 43% of ACO individuals had 4-6 other chronic conditions, while this number was lower 
among individuals with asthma-only (33%), COPD-only (36%), and no-asthma no-COPD 
(23%). A population survey in the US similarly found that 90% of individuals with ACO had at 
least one other co-existing condition (compared with 71% in asthma-only and 84% in COPD-
only)14.   
Trajectories of Adherence to IMT among Patients with ACO 
 We identified four distinct patterns of medication adherence: (1) persistent low 
adherence; (2) persistent high adherence; (3) progression to low adherence; (4) and progression 
to high adherence. The majority of older adults (57%) had persistent poor adherence and only 
11% had “persistent high adherence.” As there are no published studies on medication adherence 
trajectories over time among older adults with ACO, we compare our results to studies that 
focused on adults with asthma or COPD. Our study findings are consistent with published 
studies that have reported low adherence to maintenance therapy among individuals with either 
asthma or COPD. A recent study conducted in Australia reported that the “persistent low 
adherence” trajectory to IMT was observed among 58% of individuals with asthma who were 
between 12 and 45 years old 25. Studies that use PDC for measuring medication adherence also 
reported the high prevalence of medication non-adherence (<80% PDC) among patients with 
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asthma or COPD. For example, a systematic review of 39 clinical trials reported that only 47% to 
57% of individuals with asthma were adherent to maintenance therapy27. Similarly, a study of 
244 patients with COPD reported that adherence to maintenance therapy with ICS/LABA was 
less than 23%28. Poor adherence to maintenance therapy was reported particularly higher among 
the elderly population. In a retrospective cohort study on Medicare beneficiaries with COPD, the 
average monthly adherence to IMT was plateaued at 0.35 by the seventh month31.  
Type of IMT and Trajectories of Adherence among Patients with ACO 
 In our study cohort of older adults with ACO, 26.8% were initiated on ICS monotherapy 
and 73.2% were initiated on ICS/LABA. This means that the percentage of older adults with 
ACO who used ICS/LABA for IMT is three times higher than those who used ICS for IMT.  
An important finding of this study is that older adults who were initiated on ICS/LABA were less 
likely to have “persistent low adherence”. Previous studies among patients with asthma also 
support this finding. A clinical trial conducted by Perrin et al. reported that adherence to 
ICS/LABA was higher as compared to  ICS monotherapy142. Similarly, two other studies among 
the patient with asthma concluded that  that use of ICS/LABA is likely to improve adherence to 
IMT compared with ICS 120,121. As stated in the Introduction, ICS/LABA confers many 
advantages. Although many patients perceive that inhalers are effective in relieving the 
symptom, this perceived efficacy of ICS/LABA may be higher. This higher perceived efficacy 
can be due to a faster improvement of symptoms by using ICS/LABA. A previous clinical trial 
among patients with asthma has reported that ICS/LABA resulted in a faster improvement in 
asthma symptoms compared to ICS monotherapy for IMT143.  
5.2 Implications and Suggestions for Future Research 
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Our study findings highlight the need for a “holistic management” of older adults with chronic 
respiratory conditions, specifically ACO, asthma, and COPD.  Given many with chronic 
respiratory conditions need to see multiple providers and use multiple medications concurrently 
(example: inhaled corticosteroids,  short- and long acting beta agonist) for managing their 
respiratory symptoms110 and other medications to manage their chronic conditions), the risks of 
fragmented care and drug-disease and drug-drug interactions are very high. These factors often 
lead greater economic burden, as evidenced by our study. Although  CMS began reimbursing 
providers for providing coordinated care for those with multiple conditions in 201589, it remains 
to be seen whether such fiscal incentives for care coordination have resulted in less fragmented 
care and reduce healthcare expenditures. In this context, patients with chronic respiratory 
conditions (ACO, and COPD) may need to be managed in patient-centered medical homes that 
are “comprehensive, team-based, coordinated, accessible, and focused on quality and safety.” 90. 
As documented in published literature, pharmacists can play an important role in medical homes 
by counseling patients and/or caregivers, reviewing inhaler techniques, simplifying medication 
regiments, and providing adherence assessments91–93. Such management may improve not only 
outcomes, but also lower the economic burden of patients, payers, and health systems.  
 Our study’s findings highlight the need for developing guidelines for management of 
multiple chronic conditions. Applying “single-disease focused” clinical practice guidelines can 
result in adverse drug-drug and drug-disease interactions. A systematic review of 
recommendations in 12 UK national clinical guidelines identified that potentially serious drug-
drug interactions were common94. Adherence to guidelines for those with multiple chronic 
conditions can also generate more low-value care and lead to higher healthcare expenditures the 
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patient, payers, and the society95,96. Guidelines which focus on overlapping or larger scale care 
would benefit patients with multiple comorbidities.    
 Reducing the number of medications may directly reduce the likelihood of CRN and 
indirectly alleviate the high burden of OOP prescription cost among older adults with ACO. As 
documented in published literature, clinicians and pharmacists can play an important role in 
reducing the number of medications. For example, during annual wellness visits—now covered 
by Medicare—a comprehensive review of medications can be performed and highlights 
opportunities for prescription regimen optimization113. Providers can proactively participate in 
deprescribing by: (1) discontinuing unnecessary therapy, (2) discontinuing duplicate therapies, 
(3) combining therapies as appropriate (i.e. combination inhalers), and (4) replacing high-cost 
therapies with more affordable options. In a survey of elderly Medicare beneficiaries, more than 
30% of individuals reported they did not have the chance of talking with their provider about 
their medications in the last 12 months114. Intensive, chronic care management can be optimized 
through team-based care.  
The results of this study suggest that the adherence to IMT varies over time. For example, 
one third of patients changed their adherence behavior after 6 months of starting IMT. Hence, 
there is a need to use appropriate adherence interventions at the right time. Different 
interventions can be used to address poor adherence among patients with ACO. Interventions 
such as motivational interviewing138, coaching and patient education 139, shared decision-
making140, and simplification of regimen141 can be used for improving adherence among patients 
with ACO as these interventions have successfully improved adherence among patients with 
asthma or COPD. For designing personalized medication adherence intervention at the right 
time, it is important to focus on underlying factors associated with poor adherence. Previous 
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studies have suggested that patient-related, socioeconomic-related, health system–related, 
condition-related, and therapy-related are contributed to poor adherence33. Among all these 
factors, therapy related factors may be the least expensive modifiable factors among all. 
Frequency, length, and complexity of regimen are some of the many therapy-related factors that 
can impact adherence among patients with chronic pulmonary diseases144. One important 
therapy-related factor for IMT among individuals with ACO may be IMT type. Future 
randomized clinical trials are needed to investigate the differences in improvement of symptoms 
between ICS/LABA and ICS for IMT of ACO. 
5.3 Strengths and Limitations  
The strengths of this study are: (1) use of a nationally representative survey of elderly 
Medicare beneficiaries linked to their fee-for-service claims data (Aims 1 & 2); (2) inclusion of a 
comprehensive set of factors by using a strong framework for all aims; (3) examination of 
leading drivers of the excess burden with advanced econometric techniques; (4) contribution to 
knowledge gap by being the first study to examine the impact of medication type on adherence to 
IMT (Aim 3); (5) use of real-world data from Medicare advantage database adults (Aim 3); (6) 
adoption of longitudinal study design with adjustments for observed selection bias by using 
IPTW (Aim 3) and; (7) and use of GBTM techniques (Aim 3) to identify adherence trajectories 
over time. 
Some limitations of the proposed research should be noted. Lack of information on the 
severity of asthma and COPD is a limitation of this study. While some of the advanced methods 
shed light on drivers of the excess economic burden and medication adherence over time, they 
cannot explain reasons behind these issues. The study findings are not generalizable to all older 
adults.  Furthermore Aims 1 and 2 used cross sectional design and therefore cannot be used for 
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establishing causal inference.  Our measure of CRN was not specific to ACO medications. In 
aim 3, we did not have information on sociodemographic characteristics which may affect 
adherence and therefore we may have overestimated they effect of IMT type on adherence over 
time. Furthermore, by using prescription fill data (Aim 3) and not actual use of medications to 
define adherence, we may have not accurately measured medication adherence.  
5.5 Conclusion 
Overall among older adults, ACO was associated with excess economic burden (in terms 
of total healthcare, third-party expenditures and OOP spending burden), even after adjusting with 
a comprehensive list of variables. Post regression decomposition analyses revealed multiple 
medications use and high levels of fragmented care were the leading drivers of the excess 
economic burden. Older adults with ACO were also vulnerable for any CRN and its specific 
forms. The high number of medications used among ACO individuals explained the association 
of ACO to CRN. Furthermore, only one in 10 older adults with ACO had “persistent high 
adherence” to IMT and nearly six in 10 older adults had “persistent low adherence” to IMT. Our 
study’s findings suggest that using ICS/LABA for IMT may reduce the risk of “persistent low 
adherence” over time among older adults with ACO. Individual, policy, and program 
interventions that facilitate coordination of care may reduce the excess economic burden, and 
CRN of older adults with chronic respiratory conditions, specifically ACO. Our study’s findings 
highlight the need for heightened surveillance of ACO patients, policies and programs to reduce 
the economic burden on patients, and holistic management of ACO patients within integrated 
systems of healthcare delivery. Future prospective cohort studies are needed to confirm the study 
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7.  Appendices 
Appendix 7.1 






Number of individuls who are enrolled in fee-for-service program
38,089
Number of individuls without ghost id
39,295
Number of individuals who were alive during calendar year
39,446
Number of individuls with community-dwelling status
41,819
Number of individuals with at least one full year enrollment
68,352
Number of individuls at least 65 yeas old
74,689





Diagnosis Codes for Asthma and COPD  














































Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare Beneficiaries 
  N Wt. % 
ALL 38,089 100.0 
Sex   
 Female   21,469  56.2 
 Male   16,620  43.8 
Age in Years   
 65-74   15,107  47.5 
 75-84   15,648  37.5 
 85 and above     7,334  15.1 
Race/Ethnicity   
 White   31,529  82.6 
 Black     2,603  6.7 
 Latino     2,145  5.7 
 Other race     1,733  4.8 
Marital Status   
 Married   19,775  54.2 
 Not married   18,298  45.7 
Education   
 Less than high school     9,256  22.2 
 High school   13,751  35.5 
 Above high school   14,935  41.9 
Poverty Status   
 Less than 200% FPL   18,382  45.6 
 At least 200% FPL   19,707  54.4 
Prescription Coverage   
 Yes   23,700  61.6 
 No   14,389  38.4 
Number of Unique Medications   
 0     1,714  5.1 
 1-4     9,266  25.3 
 5-7     9,008  23.5 
 8-11     8,897  22.8 
 12 and more     9,204  23.4 




 0-1     7,845  22.3 
 2-3   20,286  53.0 
 4-6     9,949  24.6 
Calendar Year   
 2006     5,776  13.2 
 2007     5,382  12.3 
 2008     4,965  11.7 
 2009     4,341  11.5 
 2010     4,077  11.5 
 2011     4,634  13.4 
 2012     4,602  13.2 
 2013     4,312  13.3 
Note: Based on 38,089 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries continuously enrolled in 
fee-for-service Part A and Part B during the calendar year, alive during the calendar year.    





Mean Annual Adjusted and Unadjusted Expenditure 
Among Older (age > 65 years) Medicare Beneficiaries 
Medicare Current Beneficiary Survey, 2006-2013 
 No-Asthma 
No-COPD 





































Mean $ Sig 
(95% CI)  
Mean $ Sig 
(95% CI) 
Mean $ (SD) Mean $ Sig 
(95% CI)  
Mean $ Sig 
(95% CI)  
Mean $ (SD) Mean $ Sig 
(95% CI)  
Mean $ Sig 






























 (1,596- 1,685) 
2,102***  




 (1,594- 1,681) 
2,103***  




 (1,697- 1,787) 
2,183***  








 (2,988- 3,065) 
4,163***  




 (2,996- 3,073) 
4,157*** 




 (3,057- 3,133) 
4,461***  
 (4,354- 4,568) 











 (8,768- 9,046) 
6,266***  




 (9,621- 9,926) 
6949***  




















 (104- 126) 
103***  








 (115- 137) 
141***  




 (115- 137) 
141***  














 (543- 555) 
691***  




 (544- 556) 
689***  




 (555- 567) 
711***  














 (2,335- 2,456) 
1,242***  




 (2,449- 2,571) 
1,269*** 
(1,233- 1,305) 
Note:  Based on 38,089  person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries, continuously enrolled in fee-for-service Part A and Part B during the calendar 
year and alive during the calendar year. Incremental costs were measured using counterfactual recycled predictions performed using estimates obtained from a 2-part GLM model with log link 
and gamma distribution.  The variables in the adjusted models were selected based on Andersen’s healthcare behavioral model and include sex, age, race, marital status, poverty, education, 
prescription coverage, fragmented care, # ADL, # chronic conditions, # unique medications, overweight, smoking habit, and residency region. 





Unadjusted Odds Ratios (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from  
Separate Logistic Regressions on High Out-of-Pocket Burden 
Older (age > 65 years) Medicare Beneficiaries   
Medicare Current Beneficiary Survey, 2006-2013 
    Unadjusted Model Fully Adjusted Model 
    UOR 95% CI Sig AOR 95% CI Sig 
Asthma COPD Status      
 Asthma COPD Overlap 3.51 [ 2.96 ,  4.16]  1.31 [ 1.07 ,  1.61] ** 
 Asthma Only 1.99 [ 1.68 ,  2.36]  1.19 [ 0.99 ,  1.42]  
 COPD only 2.40 [ 2.20 ,  2.61]  1.28 [ 1.16 ,  1.42] *** 
 No asthma No COPD (ref)       
Sex        
 Female    1.14 [ 1.05 ,  1.23] ** 
 Male (ref)       
Age in Years    1.02 [ 1.01 ,  1.02]  
Race/Ethnicity       
 White (ref)       
 Black    0.82 [ 0.72 ,  0.94] ** 
 Latino    0.68 [ 0.56 ,  0.83] *** 
 Other Races    0.60 [ 0.50 ,  0.72] *** 
Marital Status       
 Married    0.69 [ 0.64 ,  0.74] *** 
 Not married (ref)       
Education       
 Less than high school (ref)       
 High school    0.77 [ 0.68 ,  0.86] *** 
 Above high school     0.93 [ 0.84 ,  1.03]  
Poverty Status       
 Less than 200% FPL    3.71 [ 3.44 ,  4.00] *** 
 At least 200% FPL (ref)       
Prescription Coverage       
 Yes    0.56 [ 0.52 ,  0.60] *** 
 No (ref)       
% Fragmented Care    1.01 [ 1.01 ,  1.01] *** 
# Other Chronic Conditions    1.05 [ 1.02 ,  1.09] *** 
# ADL    1.12 [ 1.09 ,  1.15] *** 
# Unique Medications    1.09 [ 1.08 ,  1.10] *** 
Overweight       
 Yes    1.01 [ 0.94 ,  1.10]  
 No (ref)       
Smoking habit       
 Current and Past    1.14 [ 0.93 ,  1.34]  
 Never (ref)       
Residency Region       
 Northeast    0.95 [ 0.81 ,  1.11]  
 South    0.79 [ 0.71 ,  0.87] *** 
 Midwest    0.90 [ 0.80 ,  1.01]  





Post-Regression Decomposition Analyses  
Older (age > 65 years) Medicare Beneficiaries 
Medicare Current Beneficiary Survey, 2006-2013 
Average Log Total Healthcare Expenditures of asthma COPD overlap 23.3893 
Average Log Total Expenditures of asthma only group 20.1912 
Difference in Log Total Healthcare Expenditures 11.1627 
Total “explained” percentage 76.42 
% Contribution to the “Explained” Portion 
Predisposing characteristics (sex, age, race) 3.70 % 
Enabling factors 1 (marital status, poverty, education, prescription coverage) -3.75% 
Enabling factor 2 (fragmented care) 11.48%* 
Need Factors 1 (# ADL, # chronic conditions) 42.05% 
Need Factors 2 (# unique medications) 76.73%* 
Personal healthcare practice (obesity, smoking) -21.12% 
External factors (residency region) -9.08% 
Average Log Total Healthcare Expenditures of asthma COPD overlap 20.8304 
Average Log Total Expenditures of COPD only group 20.0288 
Difference in Log Total Healthcare Expenditures 0.080157 
Total “explained” percentage 45.12% 
% Contribution to the “Explained” Portion 
Predisposing characteristics (sex, age, race) -109.10% 
Enabling factors 1 (marital status, poverty, education, prescription coverage) 32.61% 
Enabling factor 2 (fragmented care) 29.12% 
Need Factors 1 (# ADL, # chronic conditions) 28.19% 
Need Factors 2 (# unique medications) 61.51%*** 
Personal healthcare practice (obesity, smoking) 56.63% 
External factors (residency region) 1.04% 
 
 
Notes: Based on 38,089 elderly Medicare beneficiaries who were observed between years 2006 and 2013. The percent differences 












Number of individuls wihout any missing values for cost-related medication non-adherence
37,571
Number of individuals whose information was available in both "access to care" and "cost and use" files
37,817
Number of individuls who are enrolled in fee-for-service program
61,870
Number of individuals who were alive during calendar year
63,923
Number of individuls with community-dwelling status
68,512
Number of individuals with at least one full year enrollment
70,470
Number of individuls at least 65 yeas old
74,689





Characteristics of Elderly Community-Dwelling Fee-for-Service Medicare Beneficiaries 
  N Wt. % 
ALL 37,571 100.0 
Sex   
 Female        21,186  56.2 
 Male        16,385  43.8 
Age in Years   
 65-74        14,893  47.4 
 75-84        15,447  37.5 
 85 and above          7,231  15.1 
Race/Ethnicity   
 White        31,130  82.7 
 Black          2,563  6.6 
 Latino          2,112  5.7 
 Other race          1,688  4.8 
Marital Status   
 Married        19,507  54.2 
 Not married        18,050  45.7 
Education   
 Less than high school          9,145  22.2 
 High school        13,573  35.5 
 Above high school        14,711  41.9 
Poverty Status   
 Less than 200% FPL        18,120  45.6 
 At least 200% FPL        19,451  54.4 
Prescription Coverage   
 Yes        23,380  61.6 
 No        14,191  38.4 
OOP High Burden-Prescription Costs   
 Yes          1,805  4.5 
 No        35,766  95.5 
OOP High Burden – Medical Costs   
 Yes          4,885  12.3 
 No        32,686  87.7 
Number of Unique Medications   
 0          1,665  5.0 
 1-4          9,142  25.3 
 5-7          8,906  23.5 
 8-11          8,810  22.9 
 12 and more          9,048  23.3 
Number of Other Chronic Conditions   
 0-1          7,687  22.2 
 2-3        20,037  53.1 
 4-6          9,842  24.7 
Calendar Year   
 2006           5,694  13.2 
 2007           5,321  12.3 
 2008           4,904  11.7 
 2009           4,265  11.4 
 2010           4,001  11.4 
 2011           4,581  13.4 
 2012           4,546  13.2 
 2013           4,259  13.3 
Note: Based on 37,571 person-years of community-dwelling elderly (age > 65 years) Medicare beneficiaries 
continuously enrolled in fee-for-service Part A and Part B during the calendar year, alive during the calendar year, 
had information in both cost and use and access to care files and did not have missing information on any cost-
related medication nonadherence measures.    











Number of individuals who used ICs 
or ICS/LABA 2007-2017
• 250,508
Number of individuals who initiated 
maintenance therapy 2008-2017
• 204,997
Number of individuals with age at 
least 65 years old
• 56,650
Number of individuls with Medicare 
plans
• 48,163
Number of individuals with at least 
one year baseline and one year 
follow-up continouse enrollment
• 15,956
Number of individuls with asthma 
COPD overlap diagnosis in baseline
• 2,241
Number of individuals who did not 
use LABA or LAMA during 
baseline
• 1,562
Number of individuls wihout any 
missing values for region
• 1,554
Number of individuals on ICS
• 417






Adjusted Odds Ratios (AOR) and 95% Confidence Intervals from  
Generalized Estimating Equation (GEE) on Adherence 
among older adults with ACO Who Newly Initiated Maintenance Therapy 
Optum Clinformatics 10% Sample, 2008-2016 
 
 
Note: Based on 1,556 Medicare beneficiaries (age > 65 years old) with ACO diagnosis and newly IMT (either 
ICS or ICS/LABA) who were continuously enrolled 24 months during the observation period. In the graph, we 
only illustrated the variables with significant association with adherence. The GEE model was adjusted by time, 
square time and all factors based on Andersen’s model.  
Abbreviations: ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist; 











Characteristics of Older Adults with Asthma-COPD Overlap 
by Initial Maintenance Therapy Options 
before Using Inverse Probability Treatment Weighting 
Optum Clinformatics 10% Sample, 2007-2017 
  Total ICS/LABA ICS Sig 













ALL 1554 100.0 1137 73.2 417 26.8  
Sex        +  
Female 1035 66.6 743 65.3 292 70.0   
Male 519 33.4 394 34.7 125 30.0  
Age 75.2 6.1 75.7 6.3  75.0 6.1  
Insurance Plan       ***  
HMO 1009 64.9 709 62.4 300 71.9   
Non- HMO 545 35.1 428 37.6 117 28.1  
OOP Prescription Costs (per $100) 5.4 7.4 5.3 7.0 5.9 9.1  
Depression        
 Yes 201 12.9 142 12.5 59 14.1  
 No 1353 87.1 995 87.5 358 85.9  
Anxiety       * 
 Yes 163 10.5 108 9.5 55 13.2  
 No 1391 89.5 1029 90.5 362 86.8  
Diabetes         
 Yes 569 36.6 410 36.1 159 38.1  
 No 985 63.4 727 63.9 258 61.9  
Hypertension        
 Yes 1105 71.1 805 70.8 300 71.9  
 No 449 28.9 332 29.2 117 28.1  
Heart Diseases         
 Yes 652 42.0 480 42.2 172 41.2  
 No 902 58.0 657 57.8 245 58.8  
# Other Chronic Conditions         
 0 132 8.5 107 9.4 25 6.0  
 1-2 444 28.6 327 28.8 117 28.1  
 3-4  601 38.7 426 37.5 175 42.0  
 5 and more 377 24.3 277 24.4 100 24.0  
# SABA         * 
 0 573 36.9 432 38.0 141 33.8  
 1-3 758 48.8 531 46.7 227 54.4  
 4-6 142 9.1 109 9.6 33 7.9  
 > 7 81 5.2 65 5.7 16 3.8  
Polypharmacy         
 Yes 1097 70.6 794 69.8 303 72.7  
 No 457 29.4 343 30.2 114 27.3  
Obesity Diagnosis        
 Yes 260 16.7 198 17.4 62 14.9  
 No 1294 83.3 939 82.6 355 85.1  
Tobacco Use Diagnosis       + 
 Yes 196 12.6 153 13.5 43 10.3  
 No 1358 87.4 984 86.5 374 89.7  
Region        *** 
 Northeast 172 11.1 123 10.8 49 11.8  
 Midwest 273 17.6 201 17.7 72 17.3  
 South 605 38.9 477 42.0 128 30.7  
 West 504 32.4 336 29.6 168 40.3  
Note: Based on 1,556 Medicare beneficiaries (age > 65 years old) with ACO diagnosis and newly IMT (either ICS or ICS/LABA) who were 





Abbreviations: ACO: Asthma COPD Overlap; HMO: Health Maintenance Organization; ICS: Inhaled Corticosteroid; 
ICS/LABA: Fixed dose combination of inhaled corticosteroid-and-long-acting beta agonist; IMT: Initial Maintenance Therapy; N: 
Number; OOP: Out of Pocket; SABA: Short-Acting Beta Agonist; SD: Standard deviation; Sig: Significance; #: Number  
***p<.001,**.001<p<.01,*.01<p<.005,+ .05< p<.1 
